<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Evolus, Inc. (NASDAQ:EOLS) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET<br><br>Company Participants<br><br>Nareg Sagherian - VP and Head of Global IR and Corporate Communications<br>David Moatazedi - President and CEO<br>Rui Avelar - Chief Medical Officer and Head of R&D<br>Sandra Beaver - CFO<br><br>Conference Call Participants<br><br>Annabel Samimy - Stifel<br>Gangireddy Madhumitha - Stryker<br>Navann Ty - BNP Paribas<br>Doug Tsao - H.C. Wainwright<br>Serge Belanger - Needham & Company<br><br>Operator<br><br>Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Fourth Quarter and Full Year 2024 Earnings Conference Call. [Operator Instructions].</td><td>Evolus, Inc. (NASDAQ:EOLS) 2024ë…„ 4ë¶„ê¸° ì‹¤ì ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ì½œ<br>2025ë…„ 3ì›” 4ì¼ ì˜¤í›„ 4ì‹œ 30ë¶„ (ë¯¸ ë™ë¶€ì‹œê°„)<br><br>ì°¸ê°€ì<br><br>íšŒì‚¬ ì¸¡<br>Nareg Sagherian - ê¸€ë¡œë²Œ IR ë° ê¸°ì—…í™ë³´ ë¶€ì‚¬ì¥<br>David Moatazedi - ëŒ€í‘œì´ì‚¬ ì‚¬ì¥<br>Rui Avelar - ìµœê³ ì˜ë£Œì±…ì„ì ê²¸ R&D ì´ê´„<br>Sandra Beaver - ìµœê³ ì¬ë¬´ì±…ì„ì<br><br>ì• ë„ë¦¬ìŠ¤íŠ¸<br>Annabel Samimy - Stifel<br>Gangireddy Madhumitha - Stryker<br>Navann Ty - BNP Paribas<br>Doug Tsao - H.C. Wainwright<br>Serge Belanger - Needham & Company<br><br>ì§„í–‰ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, Evolusì˜ 2024ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ì½œì— ì°¸ì„í•´ ì£¼ì‹  ì—¬ëŸ¬ë¶„ì„ í™˜ì˜í•©ë‹ˆë‹¤. [ì§„í–‰ì ì•ˆë‚´ì‚¬í•­].</td></tr>
<tr><td>As a reminder, today's conference is being recorded and webcast live. All participants are in a listen-only mode. After the speaker's remarks, there will be a question-and-answer session. I would now like to turn the conference over to Nareg Sagherian, Vice President and Head of Global Investor Relations and Corporate Communications. Please go ahead. Nareg Sagherian<br><br>Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' fourth quarter 2024 financial results. Our fourth quarter and full year 2024 press release is now on our website at evolus.com.</td><td>ë‹¤ì‹œ í•œë²ˆ ì•Œë ¤ë“œë¦¬ìë©´, ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ëŠ” ë…¹í™”ë˜ë©° ì‹¤ì‹œê°„ìœ¼ë¡œ ì›¹ìºìŠ¤íŠ¸ë©ë‹ˆë‹¤. ëª¨ë“  ì°¸ê°€ìëŠ” ì²­ì·¨ ì „ìš© ëª¨ë“œë¡œ ì°¸ì—¬í•˜ê²Œ ë©ë‹ˆë‹¤. ë°œí‘œìì˜ ì—°ì„¤ì´ ëë‚œ í›„ì—ëŠ” ì§ˆì˜ì‘ë‹µ ì‹œê°„ì´ ì´ì–´ì§ˆ ì˜ˆì •ì…ë‹ˆë‹¤. ì´ì œ ê¸€ë¡œë²Œ íˆ¬ìì ê´€ê³„ ë° ê¸°ì—… ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ ë¶€ë¬¸ ë¶€ì‚¬ì¥ì¸ ë‚˜ë ‰ ì‚¬ê²Œë¦¬ì•ˆì—ê²Œ ì§„í–‰ì„ ë„˜ê¸°ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ë‚˜ë ‰ ë‹˜, ì§„í–‰í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>ë‚˜ë ‰ ì‚¬ê²Œë¦¬ì•ˆ:<br>ì§„í–‰ìë‹˜ ê°ì‚¬í•©ë‹ˆë‹¤. Evolusì˜ 2024ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œë¥¼ ê²€í† í•˜ê¸° ìœ„í•´ ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ì— ì°¸ì—¬í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ í™˜ì˜ì˜ ë§ì”€ì„ ë“œë¦½ë‹ˆë‹¤. ì €í¬ 2024ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì  ë³´ë„ìë£ŒëŠ” í˜„ì¬ ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ evolus.comì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With me today are David Moatazedi, President and Chief Executive Officer; Rui Avelar, Chief Medical Officer and Head of R&D'; and Sandra Beaver, Chief Financial Officer. Today's call will include forward-looking statements. Actual results may differ materially due to the risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and we undertake no obligation to update them. Additionally, we will discuss certain non-GAAP financial measures. These measures should be considered in addition to and not as a substitute for our GAAP results.</td><td>ì˜¤ëŠ˜ ì €ì™€ í•¨ê»˜ David Moatazedi ëŒ€í‘œì´ì‚¬ ê²¸ ìµœê³ ê²½ì˜ì, Rui Avelar ìµœê³ ì˜ë£Œì±…ì„ì ê²¸ R&D ì´ê´„, ê·¸ë¦¬ê³  Sandra Beaver ìµœê³ ì¬ë¬´ì±…ì„ìê°€ ì°¸ì„í•´ ìˆìŠµë‹ˆë‹¤.<br><br>ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ì½œì—ì„œëŠ” ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì´ í¬í•¨ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì‹¤ì œ ê²°ê³¼ëŠ” ì‹¤ì  ë³´ë„ìë£Œì™€ SEC ì œì¶œ ë¬¸ì„œì— ëª…ì‹œëœ ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ìœ¼ë¡œ ì¸í•´ í¬ê²Œ ë‹¤ë¥¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì€ í˜„ì¬ì˜ ê°€ì •ì— ê¸°ì´ˆí•˜ë©°, ë‹¹ì‚¬ëŠ” ì´ë¥¼ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ê°€ ì—†ìŠµë‹ˆë‹¤. <br><br>ë˜í•œ ë‹¹ì‚¬ëŠ” ì¼ë¶€ ë¹„(é)GAAP ì¬ë¬´ì§€í‘œì— ëŒ€í•´ ë…¼ì˜í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì§€í‘œë“¤ì€ GAAP ê¸°ì¤€ ì‹¤ì ì„ ëŒ€ì²´í•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ ë³´ì™„í•˜ëŠ” ìš©ë„ë¡œ ê³ ë ¤ë˜ì–´ì•¼ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>A reconciliation of GAAP to non-GAAP measures is included in today's earnings release. As a reminder, our earnings release and SEC filings are available on the SEC's website and on our investor relations website. Following the conclusion of today's call, a replay will be available on our website @investors.evolus.com. With that, I'll turn the call over to our CEO, David Moatazedi. David Moatazedi<br><br>Thank you, Nareg and good afternoon, everyone. 2024 was a transformative year for Evolus, marked by several key achievements that set the stage for 2025.</td><td>GAAPê³¼ non-GAAP ì¸¡ì •ì¹˜ì˜ ëŒ€ì‚¬í‘œëŠ” ì˜¤ëŠ˜ ì‹¤ì  ë°œí‘œìë£Œì— í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ ë§ì”€ë“œë¦¬ë©´, ë‹¹ì‚¬ì˜ ì‹¤ì  ë°œí‘œìë£Œì™€ SEC ì œì¶œ ë¬¸ì„œëŠ” SEC ì›¹ì‚¬ì´íŠ¸ì™€ ë‹¹ì‚¬ì˜ íˆ¬ìì ê´€ê³„(IR) ì›¹ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ì½œ ì¢…ë£Œ í›„ì—ëŠ” ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ investors.evolus.comì—ì„œ ë‹¤ì‹œë³´ê¸°ê°€ ì œê³µë  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ì œ CEOì´ì‹  ë°ì´ë¹„ë“œ ëª¨ì•„íƒ€ì œë””ê»˜ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ë°ì´ë¹„ë“œ ëª¨ì•„íƒ€ì œë””:<br>ë„¤ë ‰ê»˜ ê°ì‚¬ë“œë¦¬ë©°, ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. 2024ë…„ì€ Evolusì—ê²Œ í˜ì‹ ì ì¸ í•œ í•´ì˜€ìœ¼ë©°, 2025ë…„ì„ ìœ„í•œ ê¸°ë°˜ì„ ë‹¤ì§€ëŠ” ì—¬ëŸ¬ ì£¼ìš” ì„±ê³¼ë“¤ì´ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Starting with our objective of achieving profitability in Q4, I'm proud to say that not only did we achieve meaningful profitability in the fourth quarter, but we also delivered profitability for the full year, one year ahead of our stated goal. This profitability was enabled by revenue growth above 30% for the fifth consecutive year, further solidifying our position as the fastest growing brand in our category. We ended 2024 with the US market share approaching 14%, resulting in revenue above the top end of our original guidance. The combination of Jeuveau and now Evolysse brings together the fastest growing toxin in the US with the first innovation in HA technology in over a decade.</td><td>4ë¶„ê¸° ìˆ˜ìµì„± ë‹¬ì„±ì´ë¼ëŠ” ëª©í‘œì™€ ê´€ë ¨í•˜ì—¬, ì €ëŠ” 4ë¶„ê¸°ì— ì˜ë¯¸ ìˆëŠ” ìˆ˜ìµì„±ì„ ë‹¬ì„±í–ˆì„ ë¿ë§Œ ì•„ë‹ˆë¼, ë‹¹ì´ˆ ëª©í‘œë³´ë‹¤ 1ë…„ ì•ì„œ ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œë„ ìˆ˜ìµì„±ì„ ë‹¬ì„±í–ˆë‹¤ëŠ” ì ì„ ìë‘ìŠ¤ëŸ½ê²Œ ë§ì”€ë“œë¦½ë‹ˆë‹¤. ì´ëŸ¬í•œ ìˆ˜ìµì„± ë‹¬ì„±ì€ 5ë…„ ì—°ì† 30% ì´ìƒì˜ ë§¤ì¶œ ì„±ì¥ì— í˜ì…ì€ ê²ƒìœ¼ë¡œ, ì´ëŠ” ìš°ë¦¬ ì¹´í…Œê³ ë¦¬ì—ì„œ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ë¸Œëœë“œë¡œì„œì˜ ì…ì§€ë¥¼ ë”ìš± êµ³ê±´íˆ í–ˆìŠµë‹ˆë‹¤. 2024ë…„ì„ ë§ˆê°í•˜ë©´ì„œ ë¯¸êµ­ ì‹œì¥ì ìœ ìœ¨ì€ 14%ì— ê·¼ì ‘í–ˆê³ , ì´ëŠ” ë‹¹ì´ˆ ê°€ì´ë˜ìŠ¤ì˜ ìƒë‹¨ì„ ìƒíšŒí•˜ëŠ” ë§¤ì¶œ ì‹¤ì ìœ¼ë¡œ ì´ì–´ì¡ŒìŠµë‹ˆë‹¤. Jeuveauì™€ í˜„ì¬ì˜ Evolysseì˜ ê²°í•©ì€ ë¯¸êµ­ì—ì„œ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” í†¡ì‹  ì œí’ˆê³¼ ì§€ë‚œ 10ë…„ê°„ ìµœì´ˆì˜ HA(íˆì•Œë£¨ë¡ ì‚°) ê¸°ìˆ  í˜ì‹ ì„ í•˜ë‚˜ë¡œ í†µí•©í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Q4, we obtained CE Mark approval for the Estyme line of HA injectable gels, followed by FDA approval in February 2025 for Evolysse Form and Evolysse Smooth. This approval expands our total addressable market in the US by 78% and supports our 2025 revenue guidance of $345 million to $355 million, marking our sixth consecutive year of over 30% growth. We continue to prioritize execution. In 2024 we added over 2500 -- 2,900 new accounts, bringing our total to more than 15,000 purchasing accounts, which represents half of the toxin market that is Jeuveau. On the consumer side, Evolus rewards surpassed 1.1 million users, growing 40% over the prior year.</td><td>4ë¶„ê¸°ì— ì €í¬ëŠ” HA ì£¼ì…í˜• ê²” ì œí’ˆêµ°ì¸ Estymeì— ëŒ€í•œ CE ì¸ì¦ì„ íšë“í–ˆìœ¼ë©°, ì´ì–´ì„œ 2025ë…„ 2ì›”ì—ëŠ” Evolysse Formê³¼ Evolysse Smoothì— ëŒ€í•œ FDA ìŠ¹ì¸ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ì´ë²ˆ ìŠ¹ì¸ìœ¼ë¡œ ë¯¸êµ­ ë‚´ ì´ ì ì¬ ì‹œì¥ì´ 78% í™•ëŒ€ë˜ì—ˆìœ¼ë©°, ì´ëŠ” 2025ë…„ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ì¸ 3ì–µ 4,500ë§Œ ë‹¬ëŸ¬ì—ì„œ 3ì–µ 5,500ë§Œ ë‹¬ëŸ¬ ë‹¬ì„±ì„ ë’·ë°›ì¹¨í•©ë‹ˆë‹¤. ì´ë¡œì¨ ì €í¬ëŠ” 6ë…„ ì—°ì† 30% ì´ìƒì˜ ì„±ì¥ì„ ê¸°ë¡í•˜ê²Œ ë©ë‹ˆë‹¤. <br><br>ì €í¬ëŠ” ê³„ì†í•´ì„œ ì‹¤í–‰ë ¥ì— ì¤‘ì ì„ ë‘ê³  ìˆìŠµë‹ˆë‹¤. 2024ë…„ì—ëŠ” 2,900ê°œì˜ ì‹ ê·œ ê±°ë˜ì²˜ë¥¼ ì¶”ê°€í•˜ì—¬ ì´ êµ¬ë§¤ ê±°ë˜ì²˜ê°€ 15,000ê°œ ì´ìƒìœ¼ë¡œ ì¦ê°€í–ˆëŠ”ë°, ì´ëŠ” Jeuveauê°€ ì°¨ì§€í•˜ëŠ” í†¡ì‹  ì‹œì¥ì˜ ì ˆë°˜ì— í•´ë‹¹í•©ë‹ˆë‹¤. ì†Œë¹„ì ë¶€ë¬¸ì—ì„œëŠ” Evolus ë¦¬ì›Œë“œ í”„ë¡œê·¸ë¨ ì‚¬ìš©ìê°€ ì „ë…„ ëŒ€ë¹„ 40% ì¦ê°€í•œ 110ë§Œ ëª…ì„ ëŒíŒŒí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our international business also took a significant step forward. Our UK team celebrated two years on the market, achieving market share levels comparable to our second year in the US, reinforcing our confidence that our performance beauty strategy extends beyond the United States. We also expanded our direct presence in Australia and Spain, where both markets are experiencing strong uptake. We now have a footprint in all of the key markets that will drive our path to $100 million in international revenue by 2028. Lastly, 2024 marked the third consecutive year we provided revenue and expense guidance.</td><td>ë‹¹ì‚¬ì˜ í•´ì™¸ ì‚¬ì—…ë„ í° ì§„ì „ì„ ì´ë£¨ì—ˆìŠµë‹ˆë‹¤. ì˜êµ­ ë²•ì¸ì€ ì‹œì¥ ì§„ì¶œ 2ì£¼ë…„ì„ ë§ì´í•˜ì˜€ìœ¼ë©°, ë¯¸êµ­ ì§„ì¶œ 2ë…„ì°¨ì™€ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì˜ ì‹œì¥ ì ìœ ìœ¨ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë‹¹ì‚¬ì˜ í¼í¬ë¨¼ìŠ¤ ë·°í‹° ì „ëµì´ ë¯¸êµ­ì„ ë„˜ì–´ ì„±ê³µì ìœ¼ë¡œ í™•ì¥ë  ìˆ˜ ìˆë‹¤ëŠ” í™•ì‹ ì„ ë”ìš± ê°•í™”ì‹œì¼œ ì£¼ì—ˆìŠµë‹ˆë‹¤. ë˜í•œ í˜¸ì£¼ì™€ ìŠ¤í˜ì¸ì—ì„œ ì§ì ‘ ì§„ì¶œì„ í™•ëŒ€í–ˆìœ¼ë©°, ë‘ ì‹œì¥ ëª¨ë‘ ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ë‹¹ì‚¬ëŠ” 2028ë…„ê¹Œì§€ 1ì–µ ë‹¬ëŸ¬ì˜ í•´ì™¸ ë§¤ì¶œ ëª©í‘œ ë‹¬ì„±ì„ ì´ëŒì–´ ê°ˆ ëª¨ë“  ì£¼ìš” ì‹œì¥ì— ì§„ì¶œí•´ ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, 2024ë…„ì€ ë‹¹ì‚¬ê°€ 3ë…„ ì—°ì†ìœ¼ë¡œ ë§¤ì¶œ ë° ë¹„ìš© ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•œ í•´ê°€ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I'm proud of the team for their continued focus on execution, exceeding our top line revenue guidance while demonstrating prudent expense management resulting in operating expenses coming in at the low-end of our range. We take pride in our track record of meeting or exceeding our guidance each year, knowing that credibility is built over time. Looking Ahead the launch of Evolysse is a top priority. Since last year we have strengthened our expertise in the HA category, made key strategic hires and conducted over a dozen advisory meetings with key opinion leaders and customers.</td><td>ì €í¬ íŒ€ì€ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒíšŒí•˜ëŠ” ì‹¤ì ì„ ë‹¬ì„±í•˜ëŠ” ë™ì‹œì— ì‹ ì¤‘í•œ ë¹„ìš© ê´€ë¦¬ë¥¼ í†µí•´ ì˜ì—…ë¹„ìš©ì„ ê°€ì´ë˜ìŠ¤ í•˜ë‹¨ì—ì„œ ìœ ì§€í•˜ëŠ” ë“± ì§€ì†ì ì¸ ì‹¤í–‰ë ¥ì„ ë³´ì—¬ì£¼ì—ˆë‹¤ëŠ” ì ì—ì„œ ìë¶€ì‹¬ì„ ëŠë‚ë‹ˆë‹¤. ì €í¬ëŠ” ì‹ ë¢°ë„ê°€ ì‹œê°„ì„ ë‘ê³  ìŒ“ì—¬ê°„ë‹¤ëŠ” ê²ƒì„ ì•Œê¸°ì—, ë§¤ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ë‹¬ì„±í•˜ê±°ë‚˜ ì´ˆê³¼ ë‹¬ì„±í•´ì˜¨ ì‹¤ì ì„ ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. í–¥í›„ ì „ë§ê³¼ ê´€ë ¨í•˜ì—¬ Evolysse ì¶œì‹œê°€ ìµœìš°ì„  ê³¼ì œì…ë‹ˆë‹¤. ì‘ë…„ë¶€í„° ì €í¬ëŠ” HA(íˆì•Œë£¨ë¡ ì‚°) ì¹´í…Œê³ ë¦¬ì—ì„œì˜ ì „ë¬¸ì„±ì„ ê°•í™”í•˜ê³ , í•µì‹¬ ì¸ì¬ë¥¼ ì „ëµì ìœ¼ë¡œ ì˜ì…í–ˆìœ¼ë©°, ì£¼ìš” ì˜¤í”¼ë‹ˆì–¸ ë¦¬ë”ë“¤ê³¼ ê³ ê°ë“¤ì„ ëŒ€ìƒìœ¼ë¡œ ì‹­ì—¬ ì°¨ë¡€ì˜ ìë¬¸ ë¯¸íŒ…ì„ ì§„í–‰í•´ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We captured insights on the current usage of HA products, their experience from prior product launches, and the value of our innovative COLD-X technology brings to our customers and the patients. These insights, combined with additional market research have shaped our launch plans and we are prepared to commercialize Evolysse early in Q2. The R& D team did an outstanding job delivering a differentiated clinical package and a first in class label with the mention of weight loss as a cause of facial wrinkles. Rui will provide more details later in the call. Our digital strategy has already begun with the Evolysse website and social media pages now live.</td><td>HA ì œí’ˆì˜ í˜„ì¬ ì‚¬ìš© í˜„í™©, ì´ì „ ì œí’ˆ ì¶œì‹œ ê²½í—˜, ê·¸ë¦¬ê³  í˜ì‹ ì ì¸ COLD-X ê¸°ìˆ ì´ ê³ ê°ê³¼ í™˜ìë“¤ì—ê²Œ ì œê³µí•˜ëŠ” ê°€ì¹˜ì— ëŒ€í•œ ì¸ì‚¬ì´íŠ¸ë¥¼ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¸ì‚¬ì´íŠ¸ì™€ ì¶”ê°€ ì‹œì¥ ì¡°ì‚¬ ê²°ê³¼ë¥¼ ë°”íƒ•ìœ¼ë¡œ ì¶œì‹œ ê³„íšì„ ìˆ˜ë¦½í–ˆìœ¼ë©°, 2ë¶„ê¸° ì´ˆì— Evolysseë¥¼ ìƒìš©í™”í•  ì¤€ë¹„ê°€ ë˜ì–´ ìˆìŠµë‹ˆë‹¤. R&D íŒ€ì€ ì°¨ë³„í™”ëœ ì„ìƒ íŒ¨í‚¤ì§€ë¥¼ ê°œë°œí•˜ê³ , ì•ˆë©´ ì£¼ë¦„ì˜ ì›ì¸ìœ¼ë¡œ ì²´ì¤‘ ê°ì†Œë¥¼ ì–¸ê¸‰í•œ ìµœì´ˆì˜ ì œí’ˆ ë¼ë²¨ì„ ë§Œë“œëŠ” íƒì›”í•œ ì„±ê³¼ë¥¼ ì´ë£¨ì–´ëƒˆìŠµë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” Ruiê°€ ì´í›„ ì½œì—ì„œ ë” ìì„¸íˆ ì„¤ëª…í•  ì˜ˆì •ì…ë‹ˆë‹¤. ë””ì§€í„¸ ì „ëµì€ ì´ë¯¸ ì‹œì‘ë˜ì—ˆìœ¼ë©°, Evolysse ì›¹ì‚¬ì´íŠ¸ì™€ ì†Œì…œ ë¯¸ë””ì–´ í˜ì´ì§€ê°€ í˜„ì¬ ìš´ì˜ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We have also communicated the approval to our customer base. Our founding faculty and scientific advisors, some of whom were investigators in the Evolysse trials, will begin receiving shipments in the coming weeks to start using the product ahead of our broader Q2 rollout. At the end of March, we will host our national sales meeting to prepare our field organization for the launch of Evolysse in early Q2. Our focus will be on sampling and training providers to build confidence in the unique properties of Evolysse Form and Evolysse Smooth. As a result, we expect minimal revenue from Evolysse in Q2 with the majority of revenue expected in the back half of the year.</td><td>ë‹¹ì‚¬ëŠ” ê³ ê°ë“¤ì—ê²Œë„ ìŠ¹ì¸ ì†Œì‹ì„ ì „ë‹¬í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ì°½ë¦½ êµìˆ˜ì§„ê³¼ ê³¼í•™ ìë¬¸ë‹¨ ì¤‘ ì¼ë¶€ëŠ” Evolysse ì„ìƒì‹œí—˜ì˜ ì—°êµ¬ìì˜€ìœ¼ë©°, ì´ë“¤ì€ 2ë¶„ê¸° ì „ë©´ ì¶œì‹œì— ì•ì„œ ì œí’ˆì„ ë¨¼ì € ì‚¬ìš©í•´ë³´ê¸° ìœ„í•´ í–¥í›„ ëª‡ ì£¼ ë‚´ì— ì œí’ˆì„ ë°›ê²Œ ë  ì˜ˆì •ì…ë‹ˆë‹¤. 3ì›” ë§ì—ëŠ” 2ë¶„ê¸° ì´ˆ Evolysse ì¶œì‹œë¥¼ ìœ„í•´ í˜„ì¥ ì¡°ì§ì„ ì¤€ë¹„ì‹œí‚¤ëŠ” ì „êµ­ ì˜ì—…íšŒì˜ë¥¼ ê°œìµœí•  ì˜ˆì •ì…ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” Evolysse Formê³¼ Evolysse Smoothì˜ ê³ ìœ í•œ íŠ¹ì„±ì— ëŒ€í•œ ì˜ë£Œì§„ì˜ ì‹ ë¢°ë„ë¥¼ êµ¬ì¶•í•˜ê¸° ìœ„í•´ ìƒ˜í”Œ ì œê³µê³¼ êµìœ¡ì— ì¤‘ì ì„ ë‘˜ ê²ƒì…ë‹ˆë‹¤. ì´ì— ë”°ë¼ 2ë¶„ê¸°ì—ëŠ” Evolysseì—ì„œ ë°œìƒí•˜ëŠ” ë§¤ì¶œì´ ë¯¸ë¯¸í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ë§¤ì¶œì˜ ëŒ€ë¶€ë¶„ì€ í•˜ë°˜ê¸°ì— ë°œìƒí•  ê²ƒìœ¼ë¡œ ì „ë§ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Top of mind for our customers beyond the properties of the new HA gels is about our portfolio strategy, while we are not disclosing pricing specifics at this time for competitive reasons, I would like to share more about how we are integrating Evolysse into our portfolio. Our cash pay model enables us to offer a unique approach and during launch Evolysse will be seamlessly integrated into our existing portfolio of benefits including co-branded media and consumer rewards. This will enable customers to earn co-branded media benefits on purchases of Evolysse, in addition to Jeuveau. Our portfolio of benefits is a differentiated offering in the space.</td><td>í˜„ì¬ ê³ ê°ë“¤ì˜ ì£¼ìš” ê´€ì‹¬ì‚¬ëŠ” ìƒˆë¡œìš´ HA í•„ëŸ¬ì˜ íŠ¹ì„±ì„ ë„˜ì–´ì„œ ë‹¹ì‚¬ì˜ í¬íŠ¸í´ë¦¬ì˜¤ ì „ëµì— ìˆìŠµë‹ˆë‹¤. í˜„ ì‹œì ì—ì„œëŠ” ê²½ìŸìƒì˜ ì´ìœ ë¡œ êµ¬ì²´ì ì¸ ê°€ê²© ì •ë³´ëŠ” ê³µê°œí•˜ì§€ ì•Šê³  ìˆìœ¼ë‚˜, Evolysseë¥¼ ë‹¹ì‚¬ì˜ í¬íŠ¸í´ë¦¬ì˜¤ì— ì–´ë–»ê²Œ í†µí•©í•˜ê³  ìˆëŠ”ì§€ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ í˜„ê¸ˆê²°ì œ ëª¨ë¸ì„ í†µí•´ ë…íŠ¹í•œ ì ‘ê·¼ ë°©ì‹ì„ ì œê³µí•  ìˆ˜ ìˆìœ¼ë©°, ì¶œì‹œ ê³¼ì •ì—ì„œ EvolysseëŠ” ê³µë™ ë¸Œëœë“œ ë¯¸ë””ì–´ì™€ ì†Œë¹„ì ë¦¬ì›Œë“œë¥¼ í¬í•¨í•œ ê¸°ì¡´ì˜ í˜œíƒ í¬íŠ¸í´ë¦¬ì˜¤ì— ì›í™œí•˜ê²Œ í†µí•©ë  ê²ƒì…ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ê³ ê°ë“¤ì€ Jeuveauë¿ë§Œ ì•„ë‹ˆë¼ Evolysse êµ¬ë§¤ ì‹œì—ë„ ê³µë™ ë¸Œëœë“œ ë¯¸ë””ì–´ í˜œíƒì„ ë°›ì„ ìˆ˜ ìˆê²Œ ë©ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ í˜œíƒ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ì´ ë¶„ì•¼ì—ì„œ ì°¨ë³„í™”ëœ ì œì•ˆì´ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Additionally, our advisors and investigators view Evolysse as a premium HA gel with innovative technology and unique advantages over existing market leading fillers. Our pricing strategy reflects this differentiation while keeping Evolysse in line with leading HA products. Importantly, in our research, 99% of existing Jeuveau customers have expressed interest in trialing Evolysse and half of accounts that have not previously worked with Evolus are also interested. This presents a significant opportunity not only for Evolysse but also for Jeuveau.</td><td>ë˜í•œ, ë‹¹ì‚¬ì˜ ìë¬¸ë‹¨ê³¼ ì—°êµ¬ì§„ì€ Evolysseë¥¼ í˜ì‹ ì ì¸ ê¸°ìˆ ê³¼ ê¸°ì¡´ ì‹œì¥ ì„ ë„ í•„ëŸ¬ ëŒ€ë¹„ ë…íŠ¹í•œ ì¥ì ì„ ì§€ë‹Œ í”„ë¦¬ë¯¸ì—„ HA ì ¤ë¡œ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ê°€ê²© ì „ëµì€ ì´ëŸ¬í•œ ì°¨ë³„í™”ë¥¼ ë°˜ì˜í•˜ë©´ì„œë„ Evolysseë¥¼ ì£¼ìš” HA ì œí’ˆë“¤ê³¼ ë¹„ìŠ·í•œ ìˆ˜ì¤€ìœ¼ë¡œ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì£¼ëª©í•  ë§Œí•œ ì ì€, ë‹¹ì‚¬ì˜ ì¡°ì‚¬ì— ë”°ë¥´ë©´ ê¸°ì¡´ Jeuveau ê³ ê°ì˜ 99%ê°€ Evolysse ì‹œí—˜ ì‚¬ìš©ì— ê´€ì‹¬ì„ í‘œëª…í–ˆìœ¼ë©°, Evolusì™€ ì´ì „ì— ê±°ë˜í•˜ì§€ ì•Šì•˜ë˜ ê±°ë˜ì²˜ì˜ ì ˆë°˜ë„ ê´€ì‹¬ì„ ë³´ì´ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” Evolysseë¿ë§Œ ì•„ë‹ˆë¼ Jeuveauì—ë„ ìƒë‹¹í•œ ê¸°íšŒê°€ ë  ê²ƒìœ¼ë¡œ ì „ë§ë©ë‹ˆë‹¤.</td></tr>
<tr><td>By leveraging Jeuveau's existing momentum, we are building a synergistic portfolio that provides a comprehensive solution for both customers and consumers and benefits from our existing platform. Beyond 2025, all our long-term growth outlook remains strong, we are confident in our ability to achieve at least $700 million in revenue by 2028 with a non-GAAP operating income margin of at least 20% driven by our efficient cash pay business model and a relentless focus on digital and product innovation. I want to express my gratitude to our team, customers and shareholders for their continued trust and support.</td><td>Jeuveauì˜ ê¸°ì¡´ ì„±ì¥ ëª¨ë©˜í…€ì„ í™œìš©í•˜ì—¬, ì €í¬ëŠ” ê³ ê°ì‚¬ì™€ ì†Œë¹„ì ëª¨ë‘ì—ê²Œ í¬ê´„ì ì¸ ì†”ë£¨ì…˜ì„ ì œê³µí•˜ê³  ê¸°ì¡´ í”Œë«í¼ì˜ ì´ì ì„ ëˆ„ë¦´ ìˆ˜ ìˆëŠ” ì‹œë„ˆì§€ íš¨ê³¼ê°€ í° í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ ì´í›„ì—ë„ ì¥ê¸° ì„±ì¥ ì „ë§ì€ ì—¬ì „íˆ ê°•ì„¸ë¥¼ ë³´ì´ê³  ìˆìœ¼ë©°, íš¨ìœ¨ì ì¸ í˜„ê¸ˆ ê²°ì œ ë¹„ì¦ˆë‹ˆìŠ¤ ëª¨ë¸ê³¼ ë””ì§€í„¸ ë° ì œí’ˆ í˜ì‹ ì— ëŒ€í•œ ëŠì„ì—†ëŠ” ì§‘ì¤‘ì„ í†µí•´ 2028ë…„ê¹Œì§€ ìµœì†Œ 7ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œê³¼ ìµœì†Œ 20%ì˜ ë¹„(é)GAAP ì˜ì—…ì´ìµë¥ ì„ ë‹¬ì„±í•  ìˆ˜ ìˆë‹¤ëŠ” í™•ì‹ ì´ ìˆìŠµë‹ˆë‹¤. ì§€ì†ì ì¸ ì‹ ë¢°ì™€ ì§€ì›ì„ ë³´ë‚´ì£¼ì‹  ì €í¬ íŒ€ê³¼ ê³ ê°, ê·¸ë¦¬ê³  ì£¼ì£¼ ì—¬ëŸ¬ë¶„ê»˜ ê°ì‚¬ì˜ ë§ì”€ì„ ì „í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With a record year behind us and an even more exciting future ahead, we look forward to the imminent launch of Evolysse and delivering another year of exceptional growth in 2025. Now I'd like to turn the call over to Rui to share more insights on our injectable HA gel line Evolysse. Rui Avelar<br><br>Thank you, David. The FDA approval of Evolysse Form and Evolysse Smooth injectable Hyaluronic acid gels is a pivotal milestone for us, officially transforming us into a portfolio company. The Evolysse gels are formulated with proprietary ColdX technology, utilizing near freezing temperatures as compared to other gels that use heat.</td><td>ê¸°ë¡ì ì¸ í•œ í•´ë¥¼ ë§ˆë¬´ë¦¬í•˜ê³  ë”ìš± í¥ë¯¸ì§„ì§„í•œ ë¯¸ë˜ë¥¼ ì•ë‘ê³  ìˆëŠ” ì§€ê¸ˆ, ì €í¬ëŠ” Evolysseì˜ ì„ë°•í•œ ì¶œì‹œì™€ 2025ë…„ì˜ ë˜ ë‹¤ë¥¸ íƒì›”í•œ ì„±ì¥ì„ ì´ë¤„ë‚¼ ê²ƒì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ Ruiì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê²¨ ë‹¹ì‚¬ì˜ HA ì£¼ì…í˜• ì ¤ ë¼ì¸ì¸ Evolysseì— ëŒ€í•´ ë” ìì„¸í•œ ì„¤ëª…ì„ ë“¤ì–´ë³´ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. Rui Avelarì…ë‹ˆë‹¤.<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, David. Evolysse Formê³¼ Evolysse Smooth ì£¼ì…í˜• íˆì•Œë£¨ë¡ ì‚° ì ¤ì— ëŒ€í•œ FDA ìŠ¹ì¸ì€ ì €í¬ë¥¼ í¬íŠ¸í´ë¦¬ì˜¤ ê¸°ì—…ìœ¼ë¡œ ê³µì‹ ì „í™˜ì‹œí‚¤ëŠ” ì¤‘ëŒ€í•œ ì´ì •í‘œì…ë‹ˆë‹¤. Evolysse ì ¤ì€ ì—´ì„ ì‚¬ìš©í•˜ëŠ” ë‹¤ë¥¸ ì ¤ ì œí’ˆë“¤ê³¼ ë‹¬ë¦¬, ì˜í•˜ì— ê°€ê¹Œìš´ ì˜¨ë„ë¥¼ í™œìš©í•˜ëŠ” ë…ìì ì¸ ColdX ê¸°ìˆ ë¡œ ì œì¡°ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This serves as the foundation for a platform of gels which offers a wide range of capabilities. Evolysse Smooth is a soft forgiving gel with low inflammatory profile allowing injectors greater flexibility in treatment. In Europe it's approved for very superficial applications including treating thin lines around the mouth and lips, also known as PERIORAL FINE lines. Evolysse Form is our most versatile HA injectable. When we look at our gel portfolio we see a spectrum, On one end Evolysse Sculpt which provides structure and high tissue lifting capacity. On the other end Evolysse Smooth, a very soft more liquid like gel.</td><td>ì´ëŠ” ë‹¤ì–‘í•œ ê¸°ëŠ¥ì„ ì œê³µí•˜ëŠ” ì ¤ í”Œë«í¼ì˜ ê¸°ë°˜ì´ ë©ë‹ˆë‹¤. Evolysse SmoothëŠ” ì—¼ì¦ ë°˜ì‘ì´ ë‚®ì€ ë¶€ë“œëŸ½ê³  ìˆœì‘ë„ê°€ ë†’ì€ ì ¤ë¡œ, ì‹œìˆ ì˜ê°€ ì¹˜ë£Œ ì‹œ ë” í° ìœ ì—°ì„±ì„ ë°œíœ˜í•  ìˆ˜ ìˆê²Œ í•©ë‹ˆë‹¤. ìœ ëŸ½ì—ì„œëŠ” ì…ê³¼ ì…ìˆ  ì£¼ë³€ì˜ ì”ì£¼ë¦„(ì¼ëª… PERIORAL FINE lines) ì¹˜ë£Œë¥¼ í¬í•¨í•œ ë§¤ìš° í‘œì¸µ ì‹œìˆ ì— ìŠ¹ì¸ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. Evolysse Formì€ ë‹¹ì‚¬ì˜ ê°€ì¥ ë‹¤ëª©ì  íˆì•Œë£¨ë¡ ì‚° ì£¼ì‚¬ì œì…ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ì ¤ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì‚´í´ë³´ë©´ ìŠ¤í™íŠ¸ëŸ¼ì´ ìˆëŠ”ë°, í•œìª½ ëì—ëŠ” êµ¬ì¡°ì  ì§€ì§€ë ¥ê³¼ ë†’ì€ ì¡°ì§ ë¦¬í”„íŒ… íš¨ê³¼ë¥¼ ì œê³µí•˜ëŠ” Evolysse Sculptê°€ ìˆê³ , ë‹¤ë¥¸ ìª½ ëì—ëŠ” ë§¤ìš° ë¶€ë“œëŸ½ê³  ì•¡ì²´ì— ê°€ê¹Œìš´ ì ¤ì¸ Evolysse Smoothê°€ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Right in the middle of the spectrum we have Evolysse Form with both properties of structure and suppleness. Both Evolysse Form and Evolysse Smooth are approved for the correction of moderate to severe dynamic facial wrinkles and folds. Notably, the indication is broader than just nasolabial folds. The label states that it can be used in wrinkles and folds such as nasolabial folds which allows for the treatment in other areas, for example the marionette lines. The pivotal studies used a split based design with Restylane-Lidocaine as the control for both products.</td><td>ìŠ¤í™íŠ¸ëŸ¼ì˜ ì¤‘ê°„ ì§€ì ì—ëŠ” êµ¬ì¡°ì  íŠ¹ì„±ê³¼ ìœ ì—°ì„±ì„ ëª¨ë‘ ê°–ì¶˜ Evolysse Formì´ ìˆìŠµë‹ˆë‹¤. Evolysse Formê³¼ Evolysse SmoothëŠ” ëª¨ë‘ ì¤‘ë“±ë„ì—ì„œ ì¤‘ì¦ì˜ ë™ì  ì•ˆë©´ ì£¼ë¦„ ë° íŒ”ìì£¼ë¦„ì˜ êµì •ì— ëŒ€í•´ ìŠ¹ì¸ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ì£¼ëª©í•  ë§Œí•œ ì ì€, ì ì‘ì¦ì´ ë‹¨ìˆœíˆ ë¹„êµ¬ìˆœì£¼ë¦„(ë‚˜ì†”ë¼ë¹„ì•Œ í´ë“œ)ì—ë§Œ êµ­í•œë˜ì§€ ì•ŠëŠ”ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. í—ˆê°€ ì‚¬í•­ì— ë”°ë¥´ë©´ ë¹„êµ¬ìˆœì£¼ë¦„ê³¼ ê°™ì€ ì£¼ë¦„ ë° íŒ”ìì£¼ë¦„ì— ì‚¬ìš©í•  ìˆ˜ ìˆì–´, ë§ˆë¦¬ì˜¤ë„¤íŠ¸ ë¼ì¸ê³¼ ê°™ì€ ë‹¤ë¥¸ ë¶€ìœ„ì—ë„ ì‹œìˆ ì´ ê°€ëŠ¥í•©ë‹ˆë‹¤. í•µì‹¬ ì„ìƒì‹œí—˜ì€ ë¶„í•  ê¸°ë°˜ ì„¤ê³„ë¥¼ ì‚¬ìš©í–ˆìœ¼ë©°, ë‘ ì œí’ˆ ëª¨ë‘ ë ˆìŠ¤í‹¸ë Œ-ë¦¬ë„ì¹´ì¸(Restylane-Lidocaine)ì„ ëŒ€ì¡°êµ°ìœ¼ë¡œ í™œìš©í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Looking at the results over the 12-month study period, Evolysse Form demonstrated statistical significance at all follow up time points and Evolysse Smooth at six and nine months compared to the control. In the FDA approved label. it states that the study met the primary endpoint of non-inferiority and includes the 95% confidence intervals along with the corresponding P value of less than 0.001, demonstrating statistical superiority over the control for both Evolysse Form and Evolysse Smooth. The typical patient labeling states that facial wrinkles may develop over time due to natural aging.</td><td>12ê°œì›” ì—°êµ¬ê¸°ê°„ ë™ì•ˆì˜ ê²°ê³¼ë¥¼ ì‚´í´ë³´ë©´, Evolysse Formì€ ëª¨ë“  í›„ì† ê´€ì°° ì‹œì ì—ì„œ í†µê³„ì  ìœ ì˜ì„±ì„ ë³´ì˜€ìœ¼ë©°, Evolysse SmoothëŠ” ëŒ€ì¡°êµ° ëŒ€ë¹„ 6ê°œì›” ë° 9ê°œì›” ì‹œì ì—ì„œ í†µê³„ì  ìœ ì˜ì„±ì„ ë‚˜íƒ€ëƒˆìŠµë‹ˆë‹¤. FDA ìŠ¹ì¸ ë¼ë²¨ì— ë”°ë¥´ë©´, ë³¸ ì—°êµ¬ëŠ” ë¹„ì—´ë“±ì„±ì— ëŒ€í•œ 1ì°¨ í‰ê°€ë³€ìˆ˜ë¥¼ ì¶©ì¡±í–ˆìœ¼ë©°, 95% ì‹ ë¢°êµ¬ê°„ê³¼ í•¨ê»˜ Pê°’ì´ 0.001 ë¯¸ë§Œì„ì„ ë³´ì—¬ì£¼ì–´ Evolysse Formê³¼ Evolysse Smooth ëª¨ë‘ ëŒ€ì¡°êµ° ëŒ€ë¹„ í†µê³„ì  ìš°ìˆ˜ì„±ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ì¼ë°˜ í™˜ììš© ë¼ë²¨ë§ì—ëŠ” ì•ˆë©´ ì£¼ë¦„ì´ ìì—°ì ì¸ ë…¸í™” ê³¼ì •ì— ë”°ë¼ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ë°œìƒí•  ìˆ˜ ìˆë‹¤ê³  ëª…ì‹œë˜ì–´ ìˆìŠµë‹ˆë‹¤.<br><br>Note: I maintained the product names "Evolysse Form" and "Evolysse Smooth" in their original form, as is common practice in Korean financial and medical translations. Technical terms like "statistical significance", "confidence intervals", "P value" and "non-inferiority" were translated using their standard Korean financial/medical terminology equivalents.</td></tr>
<tr><td>What's unique to our FDA approved patient labeling for both Evolysse Form and Evolysse Smooth is the language that facial wrinkles may develop after weight loss. To our knowledge, we're the first and only company to include weight loss as a cause of wrinkles in in patient labeling. We believe this additional language positions us well to address the needs of the anticipated GLP1 patient. With that, I'll turn it over to Sandra for the financials. Sandra Beaver<br><br>Thank you, Rui. I would like to begin by congratulating the Evolus team for delivering an outstanding fourth quarter and close to 2024.</td><td>Evolysse Formê³¼ Evolysse Smoothì— ëŒ€í•œ FDA ìŠ¹ì¸ í™˜ì ë¼ë²¨ë§ì—ì„œ íŠ¹ì´í•œ ì ì€ ì²´ì¤‘ ê°ëŸ‰ í›„ ì•ˆë©´ ì£¼ë¦„ì´ ë°œìƒí•  ìˆ˜ ìˆë‹¤ëŠ” ë‚´ìš©ì´ í¬í•¨ë˜ì–´ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ê°€ ì•Œê¸°ë¡œëŠ” í™˜ì ë¼ë²¨ë§ì— ì²´ì¤‘ ê°ëŸ‰ì„ ì£¼ë¦„ì˜ ì›ì¸ìœ¼ë¡œ ëª…ì‹œí•œ ìµœì´ˆì´ì ìœ ì¼í•œ ê¸°ì—…ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì¶”ê°€ ë¬¸êµ¬ëŠ” ì˜ˆìƒë˜ëŠ” GLP1 í™˜ìë“¤ì˜ ë‹ˆì¦ˆë¥¼ ì¶©ì¡±ì‹œí‚¤ëŠ” ë° ìˆì–´ ìš°ë¦¬ì—ê²Œ ìœ ë¦¬í•œ ìœ„ì¹˜ë¥¼ ì œê³µí•  ê²ƒì´ë¼ê³  ë¯¿ìŠµë‹ˆë‹¤. ì´ì œ ì¬ë¬´ í˜„í™© ë³´ê³ ë¥¼ ìœ„í•´ Sandraì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. Sandra Beaverì…ë‹ˆë‹¤.<br><br>Ruië‹˜, ê°ì‚¬í•©ë‹ˆë‹¤. ì €ëŠ” ë¨¼ì € ë›°ì–´ë‚œ 4ë¶„ê¸° ì‹¤ì ê³¼ 2024ë…„ì„ ì„±ê³µì ìœ¼ë¡œ ë§ˆë¬´ë¦¬í•œ Evolus íŒ€ì—ê²Œ ì¶•í•˜ì˜ ë§ì”€ì„ ì „í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our above market sales growth, competitive positioning and disciplined expense management enabled us to achieve profitability in the fourth quarter as expected and reached a significant milestone of full year profitability one year ahead of expectations. This accomplishment sets a strong foundation as we enter 2025, positioning us to drive sustainable revenue growth and profitability. In our fifth year of commercial operations, we have continued to demonstrate the capacity that our cash pay model has to deliver top line results and operating leverage.</td><td>ì‹œì¥ í‰ê· ì„ ìƒíšŒí•˜ëŠ” ë§¤ì¶œ ì„±ì¥, ê²½ìŸë ¥ ìˆëŠ” ì‹œì¥ í¬ì§€ì…”ë‹, ê·¸ë¦¬ê³  ì²´ê³„ì ì¸ ë¹„ìš© ê´€ë¦¬ë¥¼ í†µí•´ ì˜ˆìƒëŒ€ë¡œ 4ë¶„ê¸° í‘ìë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ê¸°ëŒ€í–ˆë˜ ê²ƒë³´ë‹¤ 1ë…„ ì•ì„œ ì—°ê°„ í‘ì ì „í™˜ì´ë¼ëŠ” ì¤‘ìš”í•œ ì´ì •í‘œë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ê³¼ëŠ” 2025ë…„ì„ ì‹œì‘í•˜ëŠ” ì‹œì ì—ì„œ ì§€ì† ê°€ëŠ¥í•œ ë§¤ì¶œ ì„±ì¥ê³¼ ìˆ˜ìµì„±ì„ ê²¬ì¸í•  ìˆ˜ ìˆëŠ” ê°•ë ¥í•œ ê¸°ë°˜ì„ ë§ˆë ¨í•´ì£¼ì—ˆìŠµë‹ˆë‹¤. ìƒì—… ìš´ì˜ 5ë…„ ì°¨ë¥¼ ë§ì´í•˜ë©´ì„œ, ë‹¹ì‚¬ì˜ í˜„ê¸ˆ ê²°ì œ ëª¨ë¸ì´ ë§¤ì¶œ ì„±ì¥ê³¼ ì˜ì—… ë ˆë²„ë¦¬ì§€ë¥¼ ì°½ì¶œí•  ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì„ ì§€ì†ì ìœ¼ë¡œ ì…ì¦í•´ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Over the five year period we have achieved nearly five times operating leverage with a revenue compounded annual growth rate of 50% as compared to non-GAAP operating expense compounded annual growth rate of 11%. The commercial launch of Evolysse starting in Q2 of this year enables further operating leverage as we continue to make meaningful progress towards our 2028 guidance of at least $700 million of revenue and at least 20% non-GAAP operating income margin. Turning to our 2024 financial results, as previously reported in our January announcement, global net revenue for the fourth quarter was $79 million, a 30% increase over the fourth quarter of 2023.</td><td>ì§€ë‚œ 5ë…„ê°„ ë‹¹ì‚¬ëŠ” ë§¤ì¶œì•¡ì˜ ì—°í‰ê·  ì„±ì¥ë¥ (CAGR) 50%ì— ë¹„í•´ ë¹„(é)GAAP ì˜ì—…ë¹„ìš©ì˜ ì—°í‰ê·  ì„±ì¥ë¥ ì€ 11%ë¥¼ ê¸°ë¡í•˜ë©°, ì•½ 5ë°°ì˜ ì˜ì—… ë ˆë²„ë¦¬ì§€ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì˜¬í•´ 2ë¶„ê¸°ë¶€í„° ì‹œì‘ë˜ëŠ” Evolysseì˜ ìƒìš©í™”ë¥¼ í†µí•´ ì¶”ê°€ì ì¸ ì˜ì—… ë ˆë²„ë¦¬ì§€ê°€ ê°€ëŠ¥í•´ì§ˆ ê²ƒì´ë©°, ì´ëŠ” 2028ë…„ê¹Œì§€ ìµœì†Œ 7ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì•¡ê³¼ ìµœì†Œ 20%ì˜ ë¹„GAAP ì˜ì—…ì´ìµë¥  ë‹¬ì„±ì´ë¼ëŠ” ë‹¹ì‚¬ì˜ ê°€ì´ë˜ìŠ¤ë¥¼ í–¥í•´ ì˜ë¯¸ ìˆëŠ” ì§„ì „ì„ ì´ë£¨ëŠ”ë° ê¸°ì—¬í•  ê²ƒì…ë‹ˆë‹¤. 2024ë…„ ì‹¤ì ê³¼ ê´€ë ¨í•˜ì—¬, 1ì›” ë°œí‘œì—ì„œ ì´ë¯¸ ë³´ê³ ëœ ë°”ì™€ ê°™ì´ 4ë¶„ê¸° ê¸€ë¡œë²Œ ìˆœë§¤ì¶œì•¡ì€ 79ë°±ë§Œ ë‹¬ëŸ¬ë¡œ, 2023ë…„ 4ë¶„ê¸° ëŒ€ë¹„ 30% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>For the full year, global net revenues was $266.3 million, representing a 32% increase over 2023 and at the top of our guidance range of $260 million to $266 million. US. product revenues accounted for approximately 95% of total sales with a customer reorder rate at approximately 70%. Notably, international revenue contribution is expected to continue to increase reflecting the strong growth trajectory of our toxin business outside the US. Sales growth in the fourth quarter and full year were driven primarily by higher volumes and market share while pricing remains stable.</td><td>ì—°ê°„ ê¸°ì¤€ ê¸€ë¡œë²Œ ìˆœë§¤ì¶œì€ 2ì–µ 6,630ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ë©°, 2023ë…„ ëŒ€ë¹„ 32% ì¦ê°€í–ˆê³  ë‹¹ì‚¬ê°€ ì œì‹œí•œ 2ì–µ 6,000ë§Œ ë‹¬ëŸ¬ì—ì„œ 2ì–µ 6,600ë§Œ ë‹¬ëŸ¬ì˜ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ ìƒë‹¨ì— ìœ„ì¹˜í–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì œí’ˆ ë§¤ì¶œì´ ì „ì²´ ë§¤ì¶œì˜ ì•½ 95%ë¥¼ ì°¨ì§€í–ˆìœ¼ë©°, ê³ ê° ì¬ì£¼ë¬¸ìœ¨ì€ ì•½ 70%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì£¼ëª©í•  ë§Œí•œ ì ì€ ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ í†¡ì‹  ì‚¬ì—…ì´ ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì´ë©´ì„œ í–¥í›„ í•´ì™¸ ë§¤ì¶œ ê¸°ì—¬ë„ê°€ ì§€ì†ì ìœ¼ë¡œ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒëœë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. 4ë¶„ê¸° ë° ì—°ê°„ ë§¤ì¶œ ì„±ì¥ì€ ì£¼ë¡œ íŒë§¤ëŸ‰ ì¦ê°€ì™€ ì‹œì¥ì ìœ ìœ¨ í™•ëŒ€ì— ê¸°ì¸í–ˆìœ¼ë©°, ê°€ê²©ì€ ì•ˆì •ì ìœ¼ë¡œ ìœ ì§€ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our reported gross margin for the fourth quarter was 66.7%, while our adjusted gross margin, which excludes the amortization of intangibles, was 67.5%, consistent with Q4 2023. For the full year, reported gross margin was 68.5%, with adjusted gross margin at 69.6%, aligned with our guidance range of 68% to 71%. Operating expense management was disciplined while supporting strategic growth initiatives. GAAP operating expenses for the fourth quarter were $54.9 million, down from $57.6 million in the third quarter. Non-GAAP operating expenses for the fourth quarter were $46.6 million compared to $49.6 million in the third quarter.</td><td>4ë¶„ê¸° ë³´ê³ ëœ ë§¤ì¶œì´ì´ìµë¥ ì€ 66.7%ì˜€ìœ¼ë©°, ë¬´í˜•ìì‚° ìƒê°ì„ ì œì™¸í•œ ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ 2023ë…„ 4ë¶„ê¸°ì™€ ë™ì¼í•œ 67.5%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œëŠ” ë³´ê³ ëœ ë§¤ì¶œì´ì´ìµë¥ ì´ 68.5%ì˜€ê³ , ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ ë‹¹ì‚¬ê°€ ì œì‹œí–ˆë˜ 68%ì—ì„œ 71% ì‚¬ì´ì˜ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì— ë¶€í•©í•˜ëŠ” 69.6%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì˜ì—…ë¹„ìš© ê´€ë¦¬ëŠ” ì „ëµì  ì„±ì¥ ì´ë‹ˆì…”í‹°ë¸Œë¥¼ ì§€ì›í•˜ë©´ì„œë„ ê·œìœ¨ìˆê²Œ ì§„í–‰ë˜ì—ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° GAAP ê¸°ì¤€ ì˜ì—…ë¹„ìš©ì€ 549ë°±ë§Œ ë‹¬ëŸ¬ë¡œ, 3ë¶„ê¸°ì˜ 576ë°±ë§Œ ë‹¬ëŸ¬ì—ì„œ ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ë¹„GAAP ê¸°ì¤€ 4ë¶„ê¸° ì˜ì—…ë¹„ìš©ì€ 466ë°±ë§Œ ë‹¬ëŸ¬ë¡œ, 3ë¶„ê¸°ì˜ 496ë°±ë§Œ ë‹¬ëŸ¬ì™€ ë¹„êµí•´ ê°ì†Œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>For the full year 2024, GAAP operating expenses totaled $216.7 million compared to $186.8 million in 2023. Non-GAAP operating expenses were $185 million in 2024 compared to $163.9 million for 2023 and at the low end of our expected expense guidance range of $185 million to $190 million. Operating expenses grew at less than half the rate of revenue 13% growth as compared to 32% revenue growth, demonstrating continued operating leverage. Operating expenses will increase in 2025, beginning to ramp in the first quarter to support the Q2 launch of Evolus.</td><td>2024ë…„ ì—°ê°„ GAAP ì˜ì—…ë¹„ìš©ì€ ì´ 2ì–µ 1,670ë§Œ ë‹¬ëŸ¬ë¡œ, 2023ë…„ì˜ 1ì–µ 8,680ë§Œ ë‹¬ëŸ¬ì™€ ë¹„êµë©ë‹ˆë‹¤. ë¹„(é)GAAP ì˜ì—…ë¹„ìš©ì€ 2024ë…„ì— 1ì–µ 8,500ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” 2023ë…„ì˜ 1ì–µ 6,390ë§Œ ë‹¬ëŸ¬ì™€ ë¹„êµí•´ ë‹¹ì‚¬ê°€ ì œì‹œí–ˆë˜ 1ì–µ 8,500ë§Œ ë‹¬ëŸ¬ì—ì„œ 1ì–µ 9,000ë§Œ ë‹¬ëŸ¬ ì‚¬ì´ì˜ ë¹„ìš© ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì˜ í•˜í•œì„ ì— í•´ë‹¹í•©ë‹ˆë‹¤. ì˜ì—…ë¹„ìš© ì¦ê°€ìœ¨ì€ 13%ë¡œ, ë§¤ì¶œ ì„±ì¥ë¥  32% ëŒ€ë¹„ ì ˆë°˜ ì´í•˜ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ë©° ì§€ì†ì ì¸ ì˜ì—… ë ˆë²„ë¦¬ì§€ íš¨ê³¼ë¥¼ ì…ì¦í–ˆìŠµë‹ˆë‹¤. 2025ë…„ì—ëŠ” 2ë¶„ê¸°ë¡œ ì˜ˆì •ëœ Evolus ì¶œì‹œë¥¼ ì§€ì›í•˜ê¸° ìœ„í•´ 1ë¶„ê¸°ë¶€í„° ì˜ì—…ë¹„ìš©ì´ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>As a reminder, non-GAAP operating expenses exclude stock-based compensation expense, revaluation of the contingent royalty obligations and depreciation and amortization. Within operating expenses, Selling General and Administrative expenses for the fourth quarter were $50.2 million, down from $52.5 million in the third quarter. This included $6.1 million of non-cash stock based compensation compared to $5.2 million in the prior quarter. For the full year 2024, SG&A expenses were $198 million, up from $165 million in 2023, reflecting investments in growth and commercial expansion.</td><td>ë‹¤ì‹œ í•œ ë²ˆ ë§ì”€ë“œë¦¬ë©´, ë¹„GAAP ì˜ì—…ë¹„ìš©ì€ ì£¼ì‹ê¸°ì¤€ë³´ìƒë¹„ìš©, ì¡°ê±´ë¶€ ë¡œì—´í‹° ì±„ë¬´ì˜ ì¬í‰ê°€, ê·¸ë¦¬ê³  ê°ê°€ìƒê°ë¹„ ë° ë¬´í˜•ìì‚°ìƒê°ë¹„ë¥¼ ì œì™¸í•œ ê¸ˆì•¡ì…ë‹ˆë‹¤. ì˜ì—…ë¹„ìš© ì¤‘ íŒë§¤ê´€ë¦¬ë¹„(SG&A)ëŠ” 4ë¶„ê¸°ì— 5,020ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” 3ë¶„ê¸°ì˜ 5,250ë§Œ ë‹¬ëŸ¬ì—ì„œ ê°ì†Œí•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ëŠ” ì „ë¶„ê¸° 520ë§Œ ë‹¬ëŸ¬ì™€ ë¹„êµí•˜ì—¬ 610ë§Œ ë‹¬ëŸ¬ì˜ ë¹„í˜„ê¸ˆì„± ì£¼ì‹ê¸°ì¤€ë³´ìƒë¹„ìš©ì„ í¬í•¨í•œ ê²ƒì…ë‹ˆë‹¤. 2024ë…„ ì—°ê°„ íŒë§¤ê´€ë¦¬ë¹„ëŠ” 1ì–µ 9,800ë§Œ ë‹¬ëŸ¬ë¡œ, 2023ë…„ì˜ 1ì–µ 6,500ë§Œ ë‹¬ëŸ¬ì—ì„œ ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ì„±ì¥ê³¼ ìƒì—…ì  í™•ì¥ì„ ìœ„í•œ íˆ¬ìë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>With our disciplined approach we achieved a significant milestone in profitability, non-GAAP operating income in the fourth quarter was $6.7 million, marking a meaningful improvement from the non-GAAP operating loss of $3.7 million in Q4 of 2023 and non-GAAP operating income of $1.1 million in Q2 of 2024. This significant achievement also enabled us to deliver full year profitability for 2024 one year earlier than expected. Both non-GAAP operating expenses and non-GAAP operating income exclude stock-based compensation expense, revaluation of the contingent royalty obligations and depreciation and amortization.</td><td>ë‹¹ì‚¬ì˜ ê·œìœ¨ìˆëŠ” ì ‘ê·¼ ë°©ì‹ì„ í†µí•´ ìˆ˜ìµì„± ì¸¡ë©´ì—ì„œ ì¤‘ìš”í•œ ì´ì •í‘œë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë¹„GAAP ì˜ì—…ì´ìµì€ 670ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆëŠ”ë°, ì´ëŠ” 2023ë…„ 4ë¶„ê¸°ì˜ ë¹„GAAP ì˜ì—…ì†ì‹¤ 370ë§Œ ë‹¬ëŸ¬ì™€ 2024ë…„ 2ë¶„ê¸°ì˜ ë¹„GAAP ì˜ì—…ì´ìµ 110ë§Œ ë‹¬ëŸ¬ ëŒ€ë¹„ í° í­ì˜ ê°œì„ ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ëŸ¬í•œ ê´„ëª©í•  ë§Œí•œ ì„±ê³¼ë¥¼ í†µí•´ ë‹¹ì´ˆ ì˜ˆìƒë³´ë‹¤ 1ë…„ ì•ì„œ 2024ë…„ ì—°ê°„ í‘ì ì „í™˜ì„ ë‹¬ì„±í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ë¹„GAAP ì˜ì—…ë¹„ìš©ê³¼ ë¹„GAAP ì˜ì—…ì´ìµ ëª¨ë‘ ì£¼ì‹ê¸°ì¤€ë³´ìƒë¹„ìš©, ì¡°ê±´ë¶€ ë¡œì—´í‹° ì±„ë¬´ ì¬í‰ê°€, ê·¸ë¦¬ê³  ê°ê°€ìƒê°ë¹„ë¥¼ ì œì™¸í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Turning to the balance sheet, we ended the fourth quarter with $87 million in cash, up from $85 million at the end of the third quarter. This increase reflects strong sales growth, efficient cash collection and prudent expense management. We continue to make steady progress towards sustainable positive cash flow. Worthy of note, we anticipate a use of cash in Q1 2025 due to the seasonality of revenue coupled with the timing of our annual bonus payments and inventory stocking to support the launch of Evolus.</td><td>ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ì‚´í´ë³´ë©´, ë‹¹ì‚¬ëŠ” 3ë¶„ê¸° ë§ 8,500ë§Œ ë‹¬ëŸ¬ì—ì„œ ì¦ê°€í•œ 8,700ë§Œ ë‹¬ëŸ¬ì˜ í˜„ê¸ˆì„ 4ë¶„ê¸° ë§ì— ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¦ê°€ëŠ” ê°•ë ¥í•œ ë§¤ì¶œ ì„±ì¥, íš¨ìœ¨ì ì¸ í˜„ê¸ˆ ìˆ˜ê¸ˆ, ê·¸ë¦¬ê³  ì‹ ì¤‘í•œ ë¹„ìš© ê´€ë¦¬ë¥¼ ë°˜ì˜í•©ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì§€ì† ê°€ëŠ¥í•œ ê¸ì •ì  í˜„ê¸ˆíë¦„ì„ í–¥í•´ ê¾¸ì¤€í•œ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ì£¼ëª©í•  ë§Œí•œ ì ì€, 2025ë…„ 1ë¶„ê¸°ì—ëŠ” ê³„ì ˆì  ë§¤ì¶œ ë³€ë™ì„±ê³¼ ë”ë¶ˆì–´ ì—°ê°„ ë³´ë„ˆìŠ¤ ì§€ê¸‰ ì‹œê¸° ë° Evolus ì¶œì‹œë¥¼ ìœ„í•œ ì¬ê³  í™•ë³´ë¡œ ì¸í•´ í˜„ê¸ˆ ì‚¬ìš©ì´ ì˜ˆìƒëœë‹¤ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Looking ahead, we remain confident that our existing liquidity will fully fund our operations to positive cash generation and support the repayment of our $125 million debt facilities in 2026 and 2027. As we look beyond 2025, we remain on track to achieve total net revenues of at least $700 million by this growth will be driven by continued performance in our neurotoxin business both in the US and internationally, along with increasing contributions from our novel line of injectable hyaluronic acid gels, which will begin launching in early Q2 2025.</td><td>ì•ìœ¼ë¡œì˜ ì „ë§ì„ ì‚´í´ë³´ë©´, ìš°ë¦¬ëŠ” í˜„ì¬ ë³´ìœ í•œ ìœ ë™ì„±ìœ¼ë¡œ ì˜ì—…í™œë™ì´ ì •ìƒì ì¸ í˜„ê¸ˆ ì°½ì¶œ ë‹¨ê³„ì— ë„ë‹¬í•  ë•Œê¹Œì§€ ì¶©ë¶„íˆ ìš´ì˜ì„ ì§€ì›í•  ìˆ˜ ìˆìœ¼ë©°, 2026ë…„ê³¼ 2027ë…„ì— ë§Œê¸°ê°€ ë„ë˜í•˜ëŠ” 1ì–µ 2,500ë§Œ ë‹¬ëŸ¬ ê·œëª¨ì˜ ë¶€ì±„ ìƒí™˜ë„ ì°¨ì§ˆì—†ì´ ì´í–‰í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ í™•ì‹ í•©ë‹ˆë‹¤. 2025ë…„ ì´í›„ë¥¼ ì „ë§í•´ë³´ë©´, ìµœì†Œ 7ì–µ ë‹¬ëŸ¬ì˜ ì´ìˆœë§¤ì¶œ ë‹¬ì„±ì´ë¼ëŠ” ëª©í‘œë¥¼ í–¥í•´ ìˆœì¡°ë¡­ê²Œ ë‚˜ì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ì€ ë¯¸êµ­ ë° í•´ì™¸ ì‹œì¥ì—ì„œ ë³´í†¡ìŠ¤ ì‚¬ì—…ì˜ ì§€ì†ì ì¸ ì„±ê³¼ì™€ ë”ë¶ˆì–´, 2025ë…„ 2ë¶„ê¸° ì´ˆë¶€í„° ì¶œì‹œë  ìƒˆë¡œìš´ íˆì•Œë£¨ë¡ ì‚° ì£¼ì…í˜• ì ¤ ì œí’ˆ ë¼ì¸ì˜ ë§¤ì¶œ ê¸°ì—¬ë„ ì¦ê°€ì— í˜ì…ì–´ ë‹¬ì„±ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Achieving this revenue milestone equates to a compounded annual growth rate of 27% from 2024, with a total addressable market that stands at approximately $6.2 billion today and is expected to grow to approximately $10 billion by 2028. Additionally, by leveraging our highly synergistic infrastructure, we expect to expand operating margin and target at least 20% by 2028. With that context in mind, I'd like to summarize our 2025 guidance. Total net revenues are expected to be between $345 million and $355 million, which represents 30% to 33% growth from our 2024 results. We anticipate that Evolysse injectable HA gels will contribute 8% to 10% of total revenue in 2025.</td><td>ì´ëŸ¬í•œ ë§¤ì¶œ ëª©í‘œ ë‹¬ì„±ì€ 2024ë…„ë¶€í„° ì—°í‰ê·  ì„±ì¥ë¥ (CAGR) 27%ì— í•´ë‹¹í•˜ë©°, í˜„ì¬ ì•½ 62ì–µ ë‹¬ëŸ¬ ê·œëª¨ì¸ ì´ ì£¼ì†Œ ê°€ëŠ¥ ì‹œì¥(TAM)ì´ 2028ë…„ê¹Œì§€ ì•½ 100ì–µ ë‹¬ëŸ¬ë¡œ ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë˜í•œ, ë‹¹ì‚¬ì˜ ê³ ë„ë¡œ ì‹œë„ˆì§€ íš¨ê³¼ê°€ ìˆëŠ” ì¸í”„ë¼ë¥¼ í™œìš©í•¨ìœ¼ë¡œì¨ ì˜ì—…ì´ìµë¥ ì´ í™•ëŒ€ë˜ì–´ 2028ë…„ê¹Œì§€ ìµœì†Œ 20%ë¥¼ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë§¥ë½ì—ì„œ 2025ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ìš”ì•½í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ ìˆœë§¤ì¶œì€ 3ì–µ 4,500ë§Œ ë‹¬ëŸ¬ì—ì„œ 3ì–µ 5,500ë§Œ ë‹¬ëŸ¬ ì‚¬ì´ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” 2024ë…„ ì‹¤ì  ëŒ€ë¹„ 30%ì—ì„œ 33% ì„±ì¥í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. Evolysse ì£¼ì…í˜• íˆì•Œë£¨ë¡ ì‚° ì ¤ì´ 2025ë…„ ì´ ë§¤ì¶œì˜ 8%ì—ì„œ 10%ë¥¼ ì°¨ì§€í•  ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Non-GAAP operating expenses are expected to be between $230 million and $240 million, driven primarily by continued investments in expanding Jeuveau in the US, scaling the Jeuveau internationally and supporting the launch of Evolus form and Evolase Smooth injectable HA gels, we expect to achieve profitability positive non-GAAP operating income on a consolidated basis for the full year 2025. Non-GAAP operating income is anticipated to be achieved after the launch of Evolution and Evolysse Smooth, with investments ramping in Q1 2025 and revenue contribution weighted toward the second half of the year, which will result in our non-GAAP operating income being concentrated in Q4 2025.</td><td>ë¹„(é)GAAP ì˜ì—…ë¹„ìš©ì€ 2ì–µ 3ì²œë§Œ ë‹¬ëŸ¬ì—ì„œ 2ì–µ 4ì²œë§Œ ë‹¬ëŸ¬ ì‚¬ì´ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ ë¯¸êµ­ ë‚´ ì£¼ë³¼ë£¨(Jeuveau) ì‚¬ì—… í™•ì¥, êµ­ì œ ì‹œì¥ì—ì„œì˜ ì£¼ë³¼ë£¨ í™•ëŒ€, ê·¸ë¦¬ê³  ì—ë³¼ëŸ¬ìŠ¤ í¼(Evolus form)ê³¼ ì—ë³¼ë¦¬ìŠ¤ ìŠ¤ë¬´ìŠ¤(Evolase Smooth) HA ì£¼ì… ì ¤ì˜ ì¶œì‹œ ì§€ì›ì„ ìœ„í•œ ì§€ì†ì ì¸ íˆ¬ìì— ê¸°ì¸í•©ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” 2025ë…„ ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ì—°ê²° ì¬ë¬´ì œí‘œ ìƒ ë¹„GAAP ì˜ì—…ì´ìµ í‘ìë¥¼ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¹„GAAP ì˜ì—…ì´ìµ ë‹¬ì„±ì€ ì—ë³¼ë£¨ì…˜(Evolution)ê³¼ ì—ë³¼ë¦¬ìŠ¤ ìŠ¤ë¬´ìŠ¤ì˜ ì¶œì‹œ ì´í›„ì— ì´ë£¨ì–´ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, 2025ë…„ 1ë¶„ê¸°ì— íˆ¬ìê°€ ì¦ê°€í•˜ê³  ë§¤ì¶œ ê¸°ì—¬ë„ëŠ” í•˜ë°˜ê¸°ì— ì§‘ì¤‘ë  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ì— ë”°ë¼ ë¹„GAAP ì˜ì—…ì´ìµì€ 2025ë…„ 4ë¶„ê¸°ì— ì§‘ì¤‘ë  ê²ƒìœ¼ë¡œ ì „ë§ë©ë‹ˆë‹¤.</td></tr>
<tr><td>As a point of note, other modeling assumptions for 2025 include quarterly interest expense of $4.5 million and full year weighted average shares outstanding of approximately $63 million. With that, I will now turn the call back to the operator to begin Q and A.</td><td>ì°¸ê³ ì‚¬í•­ìœ¼ë¡œ 2025ë…„ ëª¨ë¸ë§ ê°€ì •ì—ëŠ” ë¶„ê¸°ë³„ ì´ìë¹„ìš© 450ë§Œ ë‹¬ëŸ¬ì™€ ì—°ê°„ ê°€ì¤‘í‰ê·  ë°œí–‰ì£¼ì‹ìˆ˜ ì•½ 6,300ë§Œ ì£¼ê°€ í¬í•¨ë©ë‹ˆë‹¤. ì´ì œ ì§ˆì˜ì‘ë‹µì„ ì‹œì‘í•˜ê¸° ìœ„í•´ ì§„í–‰ìì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.<br><br>Note: The translation maintains the formal business tone while accurately conveying the financial terminology (ì´ìë¹„ìš© for "interest expense", ê°€ì¤‘í‰ê·  ë°œí–‰ì£¼ì‹ìˆ˜ for "weighted average shares outstanding"). The Korean version is natural and professional, appropriate for a Korean business audience.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Here are the key points from the earnings call in Korean:<br><br>â€¢ ì‹¤ì  í•˜ì´ë¼ì´íŠ¸:<br>- 2024ë…„ 4ë¶„ê¸° ë° ì—°ê°„ í‘ìì „í™˜ ë‹¬ì„± (ëª©í‘œë³´ë‹¤ 1ë…„ ì•ë‹¹ê¹€)<br>- ë§¤ì¶œì•¡ 2663ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 32% ì„±ì¥<br>- ë¯¸êµ­ ì‹œì¥ì ìœ ìœ¨ 14% ë‹¬ì„±<br><br>â€¢ ì‹ ì œí’ˆ ì¶œì‹œ:<br>- Evolysse Formê³¼ Evolysse Smooth (íˆì•Œë£¨ë¡ ì‚° í•„ëŸ¬) FDA ìŠ¹ì¸ íšë“<br>- 2025ë…„ 2ë¶„ê¸° ì´ˆ ì¶œì‹œ ì˜ˆì •<br>- ì „ì²´ ì‹œì¥ê·œëª¨ 78% í™•ëŒ€ íš¨ê³¼ ê¸°ëŒ€<br><br>â€¢ 2025ë…„ ê°€ì´ë˜ìŠ¤:<br>- ë§¤ì¶œ 3ì–µ4500ë§Œ~3ì–µ5500ë§Œ ë‹¬ëŸ¬ (YoY 30-33% ì„±ì¥)<br>- Evolysse ì œí’ˆì´ ì „ì²´ ë§¤ì¶œì˜ 8-10% ê¸°ì—¬ ì „ë§<br>- Non-GAAP ì˜ì—…ë¹„ìš© 2ì–µ3000ë§Œ~2ì–µ4000ë§Œ ë‹¬ëŸ¬ ì˜ˆìƒ<br><br>â€¢ ì¥ê¸° ì „ë§:<br>- 2028ë…„ê¹Œì§€ ë§¤ì¶œ 7ì–µ ë‹¬ëŸ¬ ì´ìƒ ë‹¬ì„± ëª©í‘œ<br>- Non-GAAP ì˜ì—…ì´ìµë¥  20% ì´ìƒ ë‹¬ì„± ëª©í‘œ<br>- êµ­ì œ ì‚¬ì—…ì—ì„œ 1ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ ë‹¬ì„± ê³„íš</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Question-and-Answer Session<br><br>Operator<br><br>Thank you. We'll now be conducting a question-and-answer session. [Operator Instructions] Thank you. Our first question comes from the line of Annabel Samimy with Stifel. Please proceed. Annabel Samimy<br><br>Hi everyone. Thanks for taking my questions and congratulations on a good quarter and the progress with Evolysse. So, I had a couple here I guess. First, just thinking about the challenging market conditions for us Facial injectables that Rui talked about, I guess. How do you think about the environment you're launching into? And it's great that you got the label for facial wrinkles related to GLP-1s.</td><td>ì§ˆì˜ì‘ë‹µ<br><br>ì§„í–‰ì<br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ì§„í–‰í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. [ì§„í–‰ì ì•ˆë‚´ì‚¬í•­] ê°ì‚¬í•©ë‹ˆë‹¤. ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ ìŠ¤í‹°í ì˜ ì• ë„ˆë²¨ ì‚¬ë¯¸ë¯¸ ë‹˜ê»˜ì„œ í•˜ì‹œê² ìŠµë‹ˆë‹¤. ì• ë„ˆë²¨ ì‚¬ë¯¸ë¯¸ ë‹˜, ì§ˆë¬¸í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>ì•ˆë…•í•˜ì„¸ìš”, ì—¬ëŸ¬ë¶„. ì§ˆë¬¸ì˜ ê¸°íšŒë¥¼ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì¢‹ì€ ë¶„ê¸° ì‹¤ì ê³¼ Evolysseì˜ ì§„ì „ì— ëŒ€í•´ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ëª‡ ê°€ì§€ ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. <br><br>ì²«ì§¸, Ruiê°€ ì–¸ê¸‰í•œ í˜ì´ì…œ í•„ëŸ¬ ì‹œì¥ì˜ ë„ì „ì ì¸ ìƒí™©ì— ëŒ€í•´ ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. í˜„ì¬ì˜ ì‹œì¥ í™˜ê²½ì—ì„œ ì œí’ˆì„ ì¶œì‹œí•˜ëŠ” ê²ƒì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ì‹œë‚˜ìš”? GLP-1 ê´€ë ¨ ì•ˆë©´ ì£¼ë¦„ì— ëŒ€í•œ ì ì‘ì¦ì„ ìŠ¹ì¸ë°›ìœ¼ì‹  ê²ƒì€ í›Œë¥­í•œ ì„±ê³¼ì…ë‹ˆë‹¤.</td></tr>
<tr><td>I know this is asked every quarter, but have you noticed a change in behaviors and flow into practices based on patients who are looking to get their wrinkles fixed because of the GLP-1s? So I guess that's the first question I have. Or first two questions rather. David Moatazedi<br><br>Yeah. Sort of dovetail into one another. Thanks for the question, Annabel. We continue to hear the backdrop of challenging market conditions, but we don't see that in the data that we see on the toxin market. I'll start there. The first is the toxin market's been growing in this, call it, high single digit range now for multiple consecutive years following Covid.</td><td>ë§¤ ë¶„ê¸°ë§ˆë‹¤ ë‚˜ì˜¤ëŠ” ì§ˆë¬¸ì´ì§€ë§Œ, GLP-1 ì•½ë¬¼ ë•Œë¬¸ì— ì£¼ë¦„ì„ ê°œì„ í•˜ë ¤ëŠ” í™˜ìë“¤ì˜ í–‰ë™ì´ë‚˜ ë³‘ì› ë‚´ì› íŒ¨í„´ì— ë³€í™”ê°€ ìˆì—ˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì´ê²ƒì´ ì œê°€ ê°€ì§„ ì²« ë²ˆì§¸ ì§ˆë¬¸ì…ë‹ˆë‹¤. ì•„ë‹ˆ, ë‘ ê°œì˜ ì§ˆë¬¸ì´ë„¤ìš”. David Moatazedi<br><br>ë„¤, ê·¸ ì§ˆë¬¸ë“¤ì´ ì„œë¡œ ì—°ê´€ë˜ì–´ ìˆë„¤ìš”. Annabelë‹˜, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ ì‹œì¥ ìƒí™©ì´ ì–´ë µë‹¤ëŠ” ì´ì•¼ê¸°ë¥¼ ë“£ê³  ìˆì§€ë§Œ, í†¡ì‹  ì‹œì¥ì˜ ë°ì´í„°ì—ì„œëŠ” ê·¸ëŸ¬í•œ ì–´ë ¤ì›€ì´ ë³´ì´ì§€ ì•ŠìŠµë‹ˆë‹¤. ë¨¼ì € ê·¸ ì ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í†¡ì‹  ì‹œì¥ì€ ì½”ë¡œë‚˜ ì´í›„ ì—°ì†ì ìœ¼ë¡œ ìˆ˜ë…„ê°„ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.<br><br>Note: "GLP-1" and "í†¡ì‹ (toxin)"ê³¼ ê°™ì€ ì „ë¬¸ ìš©ì–´ëŠ” ì›ë¬¸ ê·¸ëŒ€ë¡œ ìœ ì§€í•˜ë©´ì„œ, í•œêµ­ì–´ë¡œ ìì—°ìŠ¤ëŸ½ê²Œ ë²ˆì—­í–ˆìŠµë‹ˆë‹¤. ë˜í•œ "high single digit range"ëŠ” ê¸ˆìœµ/íˆ¬ì ìš©ì–´ë¡œ ìì£¼ ì‚¬ìš©ë˜ëŠ” "ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ "ë¡œ ë²ˆì—­í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And we continue to see really good strength in terms of consumer interest in entering this market and adding on a toxin. That influx of this younger generation is happening now and we've of course been a beneficiary of that as our business over indexes on this younger generation, with Juveau. Interestingly, we've talked about a basket of consumers that we track in our loyalty program to assess whether they're stretching the intervals between treatments and we're not seeing any changes in their behavior despite what we hear in the backdrop. So I'd say we have a very healthy market from that standpoint. And I'd say, largely speaking, that the HA category is also a relatively healthy market.</td><td>ì‹œì¥ ì§„ì…ê³¼ í†¡ì‹  ì‹œìˆ ì„ ë°›ê³ ì í•˜ëŠ” ì†Œë¹„ìë“¤ì˜ ê´€ì‹¬ì´ ì—¬ì „íˆ ë§¤ìš° ê°•ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì Šì€ ì„¸ëŒ€ì˜ ìœ ì…ì´ í™œë°œíˆ ì´ë£¨ì–´ì§€ê³  ìˆìœ¼ë©°, ì£¼ë³´(Juveau)ë¥¼ í†µí•´ ì´ ì Šì€ ì„¸ëŒ€ì— íŠ¹íˆ ë†’ì€ ì‹œì¥ ì ìœ ìœ¨ì„ ë³´ì´ê³  ìˆëŠ” ì €í¬ íšŒì‚¬ëŠ” ë‹¹ì—°íˆ ì´ëŸ¬í•œ ì¶”ì„¸ì˜ ìˆ˜í˜œë¥¼ ë°›ê³  ìˆìŠµë‹ˆë‹¤. í¥ë¯¸ë¡œìš´ ì ì€, ì €í¬ê°€ ë¡œì—´í‹° í”„ë¡œê·¸ë¨ì„ í†µí•´ ì¶”ì  ê´€ì°°í•˜ëŠ” ì†Œë¹„ì ê·¸ë£¹ì˜ ê²½ìš°, ì‹œì¥ì˜ ì „ë°˜ì ì¸ ë¶ˆí™•ì‹¤ì„±ì—ë„ ë¶ˆêµ¬í•˜ê³  ì‹œìˆ  ê°„ê²©ì„ ëŠ˜ë¦¬ëŠ” ë“±ì˜ í–‰ë™ ë³€í™”ëŠ” ë³´ì´ì§€ ì•Šê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì¸¡ë©´ì—ì„œ ë³¼ ë•Œ ì‹œì¥ì€ ë§¤ìš° ê±´ì „í•œ ìƒíƒœë¥¼ ìœ ì§€í•˜ê³  ìˆë‹¤ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì „ë°˜ì ìœ¼ë¡œ HA(íˆì•Œë£¨ë¡ ì‚°) ì¹´í…Œê³ ë¦¬ ì—­ì‹œ ë¹„êµì  ê±´ê°•í•œ ì‹œì¥ ìƒíƒœë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I know the last 18 to 24 months has been a bit slower than it has historically. It's worth recognizing that the filler market had an outsized benefit post Covid, and to some degree, maybe some of these patients had received more HA filler volume per treatment than they had historically. And we're starting to see that number of syringes per treatment start to normalize. And that normalization is creating a backdrop that gives it the appearance of a market that has stabilized or flattened out. But we do believe that that filler market will have growth going forward. We anticipate it will grow in this mid to high single digit in our outlook for 2028.</td><td>ì§€ë‚œ 18~24ê°œì›”ì´ ê³¼ê±°ì— ë¹„í•´ ë‹¤ì†Œ ë‘”í™”ëœ ê²ƒì€ ì‚¬ì‹¤ì…ë‹ˆë‹¤. í•„ëŸ¬ ì‹œì¥ì´ ì½”ë¡œë‚˜19 ì´í›„ ì˜ˆì™¸ì ì¸ ìˆ˜í˜œë¥¼ ì…ì—ˆë‹¤ëŠ” ì ì„ ì¸ì •í•  í•„ìš”ê°€ ìˆìŠµë‹ˆë‹¤. ì–´ëŠ ì •ë„ëŠ” í™˜ìë“¤ì´ ê³¼ê±°ì— ë¹„í•´ ì‹œìˆ ë‹¹ íˆì•Œë£¨ë¡ ì‚° í•„ëŸ¬ ìš©ëŸ‰ì„ ë” ë§ì´ íˆ¬ì—¬ë°›ì•˜ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ëŠ” ì‹œìˆ ë‹¹ ì£¼ì‚¬ê¸° ìˆ˜ê°€ ì •ìƒí™”ë˜ê¸° ì‹œì‘í•˜ëŠ” ê²ƒì„ ê´€ì°°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì •ìƒí™” ê³¼ì •ìœ¼ë¡œ ì¸í•´ ì‹œì¥ì´ ì•ˆì •í™”ë˜ê±°ë‚˜ ì •ì²´ëœ ê²ƒì²˜ëŸ¼ ë³´ì´ëŠ” ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ëŠ” í•„ëŸ¬ ì‹œì¥ì´ ì•ìœ¼ë¡œë„ ì„±ì¥í•  ê²ƒì´ë¼ê³  í™•ì‹ í•©ë‹ˆë‹¤. 2028ë…„ê¹Œì§€ì˜ ì „ë§ì—ì„œ ì¤‘ë°˜ì—ì„œ í›„ë°˜ëŒ€ì˜ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And we also believe that we have a couple of reasons to be excited because we have a new technology. It's very different in the way that this is made from other HA's on the market. And we have the ability now to tell the story a bit differently, especially with this unique label that we have that speaks to weight loss. And we of course know that that is the single largest tailwind in this category. When you look forward, those GLP patients, when they enter a set of clinics, facial injectable hyaluronic acid gels are the number one procedure they would add on for that facial volume loss. So I think having that mention in our patient label is a really important part of starting that dialogue.</td><td>ë˜í•œ ì €í¬ëŠ” ëª‡ ê°€ì§€ ê³ ë¬´ì ì¸ ìš”ì¸ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ìš°ì„  ì €í¬ëŠ” ìƒˆë¡œìš´ ê¸°ìˆ ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ê¸°ìˆ ì€ ì‹œì¥ì˜ ë‹¤ë¥¸ íˆì•Œë£¨ë¡ ì‚°(HA) ì œí’ˆë“¤ê³¼ëŠ” ë§¤ìš° ë‹¤ë¥¸ ë°©ì‹ìœ¼ë¡œ ì œì¡°ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ ì €í¬ëŠ” íŠ¹íˆ ì²´ì¤‘ ê°ëŸ‰ê³¼ ê´€ë ¨ëœ ì´ ë…íŠ¹í•œ ë¼ë²¨ë§ì„ í†µí•´ ì œí’ˆì˜ ìŠ¤í† ë¦¬ë¥¼ ì¢€ ë” ì°¨ë³„í™”í•´ì„œ ì „ë‹¬í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì €í¬ëŠ” ì´ê²ƒì´ ì´ ì¹´í…Œê³ ë¦¬ì—ì„œ ê°€ì¥ í° ì„±ì¥ ë™ë ¥ì´ë¼ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œë¥¼ ì „ë§í•´ ë³¼ ë•Œ, GLP ì¹˜ë£Œë¥¼ ë°›ëŠ” í™˜ìë“¤ì´ í´ë¦¬ë‹‰ì„ ë°©ë¬¸í•  ë•Œ ì•ˆë©´ ë³¼ë¥¨ ì†ì‹¤ì„ ë³´ì™„í•˜ê¸° ìœ„í•´ ê°€ì¥ ë¨¼ì € ì„ íƒí•˜ëŠ” ì‹œìˆ ì´ ë°”ë¡œ ì•ˆë©´ìš© íˆì•Œë£¨ë¡ ì‚° ì ¤ ì£¼ì…ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ ì œí’ˆ ë¼ë²¨ì— ì´ëŸ¬í•œ ì–¸ê¸‰ì´ ìˆë‹¤ëŠ” ê²ƒì€ í™˜ìì™€ì˜ ëŒ€í™”ë¥¼ ì‹œì‘í•˜ëŠ” ë° ìˆì–´ ë§¤ìš° ì¤‘ìš”í•œ ë¶€ë¶„ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>I was in New York last week and with a couple doctors at dinner when I mentioned that label difference, they thought that was really powerful, that that's something they would want to advertise to their patients when they talk about evolve and it gives them the ability to attract new patients into the category. Annabel Samimy<br><br>Okay, that's great to know. And if I could just ask you about how your subscription model is performing. I know you launched it recently and are you going to be sharing any metrics on enrollments in the club? I guess the way you talk about the enrollments and the consumer, you know, similar to the way you talk about the consumer loyalty program.</td><td>ì§€ë‚œì£¼ ë‰´ìš•ì—ì„œ ì˜ì‚¬ ëª‡ ë¶„ê³¼ ì €ë… ì‹ì‚¬ë¥¼ í•˜ë©´ì„œ ê·¸ ë¼ë²¨ì˜ ì°¨ì´ì ì— ëŒ€í•´ ì–¸ê¸‰í–ˆì„ ë•Œ, ê·¸ë¶„ë“¤ì€ ì´ê²ƒì´ ì •ë§ ê°•ë ¥í•œ ìš”ì†Œë¼ê³  ìƒê°í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” í™˜ìë“¤ì—ê²Œ ì´ë³¼ë¸Œ(Evolve)ì— ëŒ€í•´ ì„¤ëª…í•  ë•Œ í™ë³´í•˜ê³  ì‹¶ì€ ë¶€ë¶„ì´ë©°, ìƒˆë¡œìš´ í™˜ìë“¤ì„ ì´ ì¹´í…Œê³ ë¦¬ë¡œ ìœ ì¹˜í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ì œê³µí•œë‹¤ê³  ë³´ì•˜ìŠµë‹ˆë‹¤.<br><br>Annabel Samimy<br><br>ì•Œê² ìŠµë‹ˆë‹¤, ê·¸ê²ƒì€ ì¢‹ì€ ì†Œì‹ì´ë„¤ìš”. ê·¸ë¦¬ê³  ê°€ëŠ¥í•˜ë‹¤ë©´ êµ¬ë… ëª¨ë¸ì´ ì–´ë–»ê²Œ ìˆ˜í–‰ë˜ê³  ìˆëŠ”ì§€ ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. ìµœê·¼ì— ì¶œì‹œí•˜ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆëŠ”ë°, í´ëŸ½ ê°€ì…ì— ëŒ€í•œ ì§€í‘œë¥¼ ê³µìœ í•˜ì‹¤ ì˜ˆì •ì´ì‹ ê°€ìš”? ì†Œë¹„ì ë¡œì—´í‹° í”„ë¡œê·¸ë¨ì— ëŒ€í•´ ë§ì”€í•˜ì‹œëŠ” ê²ƒì²˜ëŸ¼, ê°€ì… í˜„í™©ê³¼ ì†Œë¹„ìì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>And are there any early metrics you can share from the injectors and whether they're seeing persistency in foot traffic and upselling opportunities? David Moatazedi<br><br>So your SMS Club Evolus subscription program, as you know, we launched that program in the back half of last year to a limited group of customers. We extended that to about roughly 100 customers around the US that had access to Club Evolus. We've seen really good results. I think we want to see a full year cycle before we share some of those results and compare them against our pilot. But we continue to see results that are in line with what you would expect at the phase of that initial introductory 100 accounts.</td><td>ì£¼ì‚¬ì‹œìˆ ìë“¤ì˜ ì´ˆê¸° ì§€í‘œì™€ ê´€ë ¨í•˜ì—¬, ê³ ê° ì¬ë°©ë¬¸ìœ¨ê³¼ ì¶”ê°€ íŒë§¤ ê¸°íšŒì— ëŒ€í•´ ê³µìœ í•˜ì‹¤ ìˆ˜ ìˆëŠ” ë‚´ìš©ì´ ìˆìœ¼ì‹ ê°€ìš”? David Moatazedi<br><br>ë„¤, ì €í¬ SMS Club Evolus êµ¬ë… í”„ë¡œê·¸ë¨ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, ì•„ì‹œë‹¤ì‹œí”¼ ì‘ë…„ í•˜ë°˜ê¸°ì— ì œí•œëœ ê³ ê°êµ°ì„ ëŒ€ìƒìœ¼ë¡œ ì´ í”„ë¡œê·¸ë¨ì„ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì „ì—­ì˜ ì•½ 100ì—¬ ê°œ ê³ ê°ì‚¬ì— Club Evolus ì´ìš© ê¶Œí•œì„ í™•ëŒ€í–ˆê³ , ë§¤ìš° ê¸ì •ì ì¸ ê²°ê³¼ë¥¼ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì´ëŸ¬í•œ ê²°ê³¼ë¥¼ íŒŒì¼ëŸ¿ í”„ë¡œê·¸ë¨ê³¼ ë¹„êµí•˜ì—¬ ê³µìœ í•˜ê¸° ìœ„í•´ì„œëŠ” 1ë…„ ì „ì²´ ì£¼ê¸°ì˜ ë°ì´í„°ë¥¼ í™•ë³´í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. í˜„ì¬ê¹Œì§€ëŠ” ì´ˆê¸° 100ê°œ ê³„ì • ë‹¨ê³„ì—ì„œ ê¸°ëŒ€í•  ìˆ˜ ìˆëŠ” ìˆ˜ì¤€ì˜ ê²°ê³¼ê°€ ì§€ì†ì ìœ¼ë¡œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We since opened it up more broadly to more customers and we continue to have a high amount of interest in both enrolling into our club program with existing accounts, but also once they enroll, getting them to start putting patients that are on a regular treatment interval into the subscription. That being said, I don't think comparing it to our loyalty program is the right comparator because this is an entirely new platform that these practices have not had in the past. So we're introducing a different way of selling it, we're collecting obviously a payment from the consumer in this program. And so there's a learning curve for all these clinics that they need to go through.</td><td>ì´í›„ ì €í¬ëŠ” ë” ë§ì€ ê³ ê°ë“¤ì—ê²Œ í”„ë¡œê·¸ë¨ì„ í™•ëŒ€ ê°œë°©í–ˆìœ¼ë©°, ê¸°ì¡´ ê³„ì •ì„ ê°€ì§„ ê³ ê°ë“¤ì˜ í´ëŸ½ í”„ë¡œê·¸ë¨ ë“±ë¡ì— ëŒ€í•œ ë†’ì€ ê´€ì‹¬ì´ ì§€ì†ë˜ê³  ìˆì„ ë¿ë§Œ ì•„ë‹ˆë¼, ë“±ë¡ í›„ì—ëŠ” ì •ê¸°ì ì¸ ì¹˜ë£Œê°€ í•„ìš”í•œ í™˜ìë“¤ì„ êµ¬ë… ì„œë¹„ìŠ¤ë¡œ ì „í™˜í•˜ëŠ” ë°ì—ë„ ë§ì€ ê´€ì‹¬ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ, ì´ë¥¼ ì €í¬ì˜ ë¡œì—´í‹° í”„ë¡œê·¸ë¨ê³¼ ë¹„êµí•˜ëŠ” ê²ƒì€ ì ì ˆí•˜ì§€ ì•Šë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ëŠ” ì´ì „ì— ì´ëŸ¬í•œ ë³‘ì›ë“¤ì´ ì „í˜€ ê²½í—˜í•´ë³´ì§€ ëª»í•œ ì™„ì „íˆ ìƒˆë¡œìš´ í”Œë«í¼ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì €í¬ëŠ” ìƒˆë¡œìš´ íŒë§¤ ë°©ì‹ì„ ë„ì…í•˜ê³  ìˆìœ¼ë©°, ì´ í”„ë¡œê·¸ë¨ì—ì„œëŠ” ì†Œë¹„ìë¡œë¶€í„° ì§ì ‘ ê²°ì œë¥¼ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ëª¨ë“  í´ë¦¬ë‹‰ë“¤ì´ ì´ëŸ¬í•œ ìƒˆë¡œìš´ ì‹œìŠ¤í…œì— ì ì‘í•˜ëŠ” ë° í•™ìŠµ ê³¡ì„ ì´ í•„ìš”í•œ ìƒí™©ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Whereas when we launched our loyalty program, they had existing loyalty programs from some of the bigger players in the space. So they were used to offering a loyalty program here. We're first in class and we're creating a new market around subscription. But I'M really pleased with the early results we're seeing. I think we'll give you a better feel for it once we wrap around right around the year on those early performance metrics. Operator<br><br>Thank you. Our next question comes from the line of Mark Goodman with Stryker. Please proceed. Gangireddy Madhumitha<br><br>This is Madhu on the line for Mark. Just a quick clarification on your last comments.</td><td>ìš°ë¦¬ê°€ ë¡œì—´í‹° í”„ë¡œê·¸ë¨ì„ ì¶œì‹œí–ˆì„ ë•ŒëŠ” ì—…ê³„ ì£¼ìš” ê¸°ì—…ë“¤ì´ ì´ë¯¸ ë¡œì—´í‹° í”„ë¡œê·¸ë¨ì„ ìš´ì˜í•˜ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ê·¸ë“¤ì€ ì´ë¯¸ ë¡œì—´í‹° í”„ë¡œê·¸ë¨ì„ ì œê³µí•˜ëŠ” ê²ƒì— ìµìˆ™í•´ì ¸ ìˆì—ˆì£ . í•˜ì§€ë§Œ êµ¬ë… ì„œë¹„ìŠ¤ ì¸¡ë©´ì—ì„œëŠ” ìš°ë¦¬ê°€ ì—…ê³„ ìµœì´ˆì´ë©°, ìƒˆë¡œìš´ ì‹œì¥ì„ ê°œì²™í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ˆê¸° ì„±ê³¼ë¥¼ ë³´ë©´ ë§¤ìš° ê³ ë¬´ì ì…ë‹ˆë‹¤. ì—°ê°„ ì‹¤ì ì´ ë§ˆë¬´ë¦¬ë˜ë©´ ì´ëŸ¬í•œ ì´ˆê¸° ì„±ê³¼ ì§€í‘œì— ëŒ€í•´ ë” ëª…í™•í•œ ê·¸ë¦¼ì„ ì œì‹œí•  ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì§„í–‰ìë‹˜.<br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ë‹¤ìŒ ì§ˆë¬¸ì€ Strykerì˜ Mark Goodman ë‹˜ ì°¨ë¡€ì…ë‹ˆë‹¤. ë§ì”€í•´ ì£¼ì‹­ì‹œì˜¤. Gangireddy Madhumitha<br><br>Markë¥¼ ëŒ€ì‹ í•´ì„œ Madhuê°€ ì§ˆë¬¸ ë“œë¦½ë‹ˆë‹¤. ë°©ê¸ˆ í•˜ì‹  ë§ì”€ì— ëŒ€í•´ ê°„ë‹¨íˆ í™•ì¸ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So just your growth expectations for the US toxin market in 2025. You know, it seems like you were saying that you're seeing something different from your competitors in terms of the fourth quarter. So just curious, on your expectations for this year, do you see the market growing maybe in the 6 to 7% range? And then regarding the fillers, can you talk about how the in vitro data you've shared versus Restylane in terms of the thermal and shear stress could translate to potentially different mechanical properties in the body? Maybe you can relate it to the clinical trial data or potential differentiation in the real-world setting. Thank you. David Moatazedi<br><br>Great.</td><td>2025ë…„ ë¯¸êµ­ í†¡ì‹  ì‹œì¥ì˜ ì„±ì¥ ì „ë§ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì™€ ê´€ë ¨í•˜ì—¬ ë‹¹ì‚¬ëŠ” ê²½ìŸì‚¬ë“¤ê³¼ëŠ” ë‹¤ë¥¸ ì–‘ìƒì„ ë³´ê³  ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì˜¬í•´ ì‹œì¥ì´ 6~7% ì •ë„ ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. <br><br>í•„ëŸ¬ì™€ ê´€ë ¨í•´ì„œëŠ”, Restylaneê³¼ ë¹„êµí•œ ì—´ ìŠ¤íŠ¸ë ˆìŠ¤ ë° ì „ë‹¨ ìŠ¤íŠ¸ë ˆìŠ¤ì— ëŒ€í•œ ì²´ì™¸ ì‹¤í—˜ ë°ì´í„°ê°€ ì‹¤ì œ ì¸ì²´ ë‚´ì—ì„œ ì–´ë–»ê²Œ ë‹¤ë¥¸ ê¸°ê³„ì  íŠ¹ì„±ìœ¼ë¡œ ì´ì–´ì§ˆ ìˆ˜ ìˆëŠ”ì§€ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì„ìƒì‹œí—˜ ë°ì´í„°ë‚˜ ì‹¤ì œ ì„ìƒ í™˜ê²½ì—ì„œì˜ ì°¨ë³„í™” ê°€ëŠ¥ì„±ê³¼ ì—°ê´€ì§€ì–´ ì„¤ëª…í•´ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤.<br><br>[ë°ì´ë¹„ë“œ ëª¨ì•„íƒ€ì œë””]<br><br>ì¢‹ìŠµë‹ˆë‹¤.<br><br>Note: The translation maintains the formal and professional tone appropriate for financial contexts while accurately conveying technical terms like "í†¡ì‹  ì‹œì¥" (toxin market), "ì²´ì™¸ ì‹¤í—˜ ë°ì´í„°" (in vitro data), and "ì „ë‹¨ ìŠ¤íŠ¸ë ˆìŠ¤" (shear stress). The question-and-answer format is preserved, and the language is natural and fluent in Korean while remaining faithful to the original meaning.</td></tr>
<tr><td>Okay, thanks for the questions. I'll make just one comment and turn it over to Sandra to talk a little bit about our guidance on market for Botoxin and filler. And then Rui to answer your question on the, on the gel properties. I just start by saying I think we recognize that as a business that's grown over 30% for five consecutive years, we're over indexing against this younger generation of consumers and we're benefiting from this new patient growth coming in the category, we have an outsized benefit on that. So I think from that standpoint, obviously we have a really great seat at the table, but we don't always have a clear view on the market.</td><td>ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì œê°€ ê°„ë‹¨íˆ ì–¸ê¸‰í•˜ê³ , Sandraì—ê²Œ ë³´í†¡ìŠ¤ì™€ í•„ëŸ¬ ì‹œì¥ì— ëŒ€í•œ ë‹¹ì‚¬ì˜ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ì„¤ëª…í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ê·¸ ë‹¤ìŒ Ruiê°€ ì ¤ íŠ¹ì„±ì— ëŒ€í•œ ì§ˆë¬¸ì— ë‹µë³€í•˜ê² ìŠµë‹ˆë‹¤. ìš°ì„  ë§ì”€ë“œë¦¬ìë©´, 5ë…„ ì—°ì† 30% ì´ìƒì˜ ì„±ì¥ì„ ì´ë£¬ ê¸°ì—…ìœ¼ë¡œì„œ, ìš°ë¦¬ëŠ” ì Šì€ ì„¸ëŒ€ì˜ ì†Œë¹„ìë“¤ì—ê²Œ ë†’ì€ ì˜í–¥ë ¥ì„ ë¯¸ì¹˜ê³  ìˆìœ¼ë©°, ì´ ì¹´í…Œê³ ë¦¬ì— ìœ ì…ë˜ëŠ” ì‹ ê·œ í™˜ì ì¦ê°€ë¡œë¶€í„° ìƒë‹¹í•œ í˜œíƒì„ ë³´ê³  ìˆë‹¤ëŠ” ì ì„ ì¸ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¸¡ë©´ì—ì„œ ìš°ë¦¬ëŠ” ë¶„ëª…íˆ ì‹œì¥ì—ì„œ ë§¤ìš° ìœ ë¦¬í•œ ìœ„ì¹˜ë¥¼ ì°¨ì§€í•˜ê³  ìˆì§€ë§Œ, í•­ìƒ ì‹œì¥ì„ ëª…í™•í•˜ê²Œ íŒŒì•…í•  ìˆ˜ ìˆëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤.</td></tr>
<tr><td>But we do see a very healthy market and we can tell you how we're thinking about this year. Sandra Beaver<br><br>Yeah, I think David elaborated on a lot of the different factors that we see driving the market. But if you look historically at the health of these markets, historically the combined filler and toxin markets have been growing in the low double digits or around 13% over the last number of years. The toxin market in particular over the last few years has been high single, and that's played out in '23 and 2024. So we continue to see that very healthy growth rate and we project overall for the long term a 10% ish. So high single to low double digit growing over both categories. Right.</td><td>í•˜ì§€ë§Œ ì €í¬ëŠ” ë§¤ìš° ê±´ì „í•œ ì‹œì¥ì„ ë³´ê³  ìˆìœ¼ë©°, ì˜¬í•´ì— ëŒ€í•œ ì €í¬ì˜ ì „ë§ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Sandra Beaverì…ë‹ˆë‹¤.<br><br>ë„¤, Davidê°€ ì‹œì¥ ì„±ì¥ì„ ê²¬ì¸í•˜ëŠ” ë‹¤ì–‘í•œ ìš”ì¸ë“¤ì— ëŒ€í•´ ìì„¸íˆ ì„¤ëª…í–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ ì‹œì¥ë“¤ì˜ ì—­ì‚¬ì  ê±´ì „ì„±ì„ ì‚´í´ë³´ë©´, í•„ëŸ¬ì™€ í†¡ì‹  ì‹œì¥ì„ í•©ì¹œ ì „ì²´ ì‹œì¥ì€ ì§€ë‚œ ìˆ˜ë…„ê°„ ë‚®ì€ ë‘ ìë¦¿ìˆ˜, ì¦‰ ì•½ 13% ì •ë„ì˜ ì„±ì¥ë¥ ì„ ë³´ì—¬ì™”ìŠµë‹ˆë‹¤. íŠ¹íˆ í†¡ì‹  ì‹œì¥ì€ ìµœê·¼ ëª‡ ë…„ê°„ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë³´ì˜€ê³ , ì´ëŠ” 2023ë…„ê³¼ 2024ë…„ì—ë„ ì´ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì´ëŸ¬í•œ ë§¤ìš° ê±´ì „í•œ ì„±ì¥ë¥ ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìœ¼ë©°, ì¥ê¸°ì ìœ¼ë¡œëŠ” ì „ì²´ì ìœ¼ë¡œ ì•½ 10% ì •ë„, ì¦‰ ë†’ì€ í•œ ìë¦¿ìˆ˜ì—ì„œ ë‚®ì€ ë‘ ìë¦¿ìˆ˜ì˜ ì„±ì¥ë¥ ì´ ë‘ ì¹´í…Œê³ ë¦¬ ëª¨ë‘ì—ì„œ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And we see a lot of great tailwinds that continue to further support that along with the entrance of the millennials. Having said that, we are very responsible in the way we think about our guidance and the way we think about setting the market for 2025, and the market that we have in 2025 does expect a relatively flat tiller market. So if we do see some of those tailwinds materialize in 2025, that would be some upside for us. As of now, we're being prudent in the way we think about the market shape and the timing of when it will start to impact.</td><td>ë°€ë ˆë‹ˆì–¼ ì„¸ëŒ€ì˜ ì‹œì¥ ì§„ì…ê³¼ í•¨ê»˜ ìš°ë¦¬ëŠ” ì´ë¥¼ ë’·ë°›ì¹¨í•˜ëŠ” ë§ì€ ê¸ì •ì ì¸ ìš”ì¸ë“¤ì„ ê³„ì†í•´ì„œ ëª©ê²©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ, ìš°ë¦¬ëŠ” 2025ë…„ ê°€ì´ë˜ìŠ¤ì™€ ì‹œì¥ ì „ë§ì„ ì„¤ì •í•˜ëŠ” ë° ìˆì–´ ë§¤ìš° ì‹ ì¤‘í•œ ì ‘ê·¼ì„ í•˜ê³  ìˆìœ¼ë©°, 2025ë…„ ì‹œì¥ì— ëŒ€í•´ì„œëŠ” í‹¸ëŸ¬(ê²½ìš´ê¸°) ì‹œì¥ì´ ë¹„êµì  ì •ì²´ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§Œì•½ 2025ë…„ì— ì•ì„œ ì–¸ê¸‰í•œ ê¸ì •ì  ìš”ì¸ë“¤ì´ ì‹¤ì œë¡œ í˜„ì‹¤í™”ëœë‹¤ë©´, ì´ëŠ” ìš°ë¦¬ì—ê²Œ ì¶”ê°€ì ì¸ ìƒìŠ¹ ìš”ì¸ì´ ë  ê²ƒì…ë‹ˆë‹¤. í˜„ì¬ë¡œì„œëŠ” ì‹œì¥ í˜•ì„±ê³¼ ì´ëŸ¬í•œ ì˜í–¥ì´ ë‚˜íƒ€ë‚˜ëŠ” ì‹œê¸°ì— ëŒ€í•´ ì‹ ì¤‘í•œ ì…ì¥ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Rui Avelar<br><br>And then just to take your last question in terms of, you know, the basic premise is using this freezing technology or near freezing, when you cross link, what we seem to do is a better job of preserving that natural structure of ha. And if you think about it, you would wonder, well, I wonder if that would mean it would resist the forces and stresses that may be applied to these gels. And that's what the benchtop data said. One way of looking at it is to thermally stress it. It's a way of seeing how stable your gel is. And what we found was these gels seem to stand up better than the competitors.</td><td>ë£¨ì´ ì•„ë²¨ë¼ë¥´<br><br>ë§ˆì§€ë§‰ ì§ˆë¬¸ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, ê¸°ë³¸ ì „ì œëŠ” ì´ ëƒ‰ë™ ê¸°ìˆ  ë˜ëŠ” ê·¼ì ‘ ëƒ‰ë™ ê¸°ìˆ ì„ ì‚¬ìš©í•  ë•Œ, í¬ë¡œìŠ¤ë§í‚¹(êµì°¨ê²°í•©)ì„ í•˜ë©´ íˆì•Œë£¨ë¡ ì‚°(HA)ì˜ ìì—° êµ¬ì¡°ë¥¼ ë” ì˜ ë³´ì¡´í•˜ëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ë¥¼ ìƒê°í•´ë³´ë©´, 'ì´ê²ƒì´ ì´ëŸ¬í•œ ì ¤ì— ê°€í•´ì§€ëŠ” í˜ê³¼ ìŠ¤íŠ¸ë ˆìŠ¤ì— ë” ì˜ ê²¬ë”œ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•˜ì§€ ì•Šì„ê¹Œ?' í•˜ëŠ” ì˜ë¬¸ì´ ë“¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‹¤í—˜ì‹¤ ë°ì´í„°ê°€ ë°”ë¡œ ê·¸ê²ƒì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ì´ë¥¼ í™•ì¸í•˜ëŠ” í•œ ë°©ë²•ì€ ì—´ ìŠ¤íŠ¸ë ˆìŠ¤ë¥¼ ê°€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì ¤ì˜ ì•ˆì •ì„±ì„ í™•ì¸í•˜ëŠ” ë°©ë²•ì¸ë°ìš”. ìš°ë¦¬ê°€ ë°œê²¬í•œ ë°”ë¡œëŠ” ì´ëŸ¬í•œ ì ¤ë“¤ì´ ê²½ìŸì‚¬ ì œí’ˆë“¤ë³´ë‹¤ ë” ìš°ìˆ˜í•œ ë‚´êµ¬ì„±ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We went up to probably a more relevant metric when we look at testing these gels kind of on the benchtop, is that compression and shear. So if we think about laying on one's face or moving one's lips or just facial movement, that also translated really well. What we found was that these Evolysse gels seem to withstand that compression and shear force way better than the competitors. And then ultimately your question is how does that translate in clinical. And that's what was nice to see in the European study when we put these gels into the nasolabial folds and they were controlled, so you had a control on one side.</td><td>ë²¤ì¹˜íƒ‘ì—ì„œ ì´ëŸ¬í•œ ì ¤ì„ í…ŒìŠ¤íŠ¸í•  ë•Œ ë”ìš± ê´€ë ¨ì„± ìˆëŠ” ì§€í‘œì¸ ì••ì¶•ê³¼ ì „ë‹¨ë ¥ìœ¼ë¡œ ë„˜ì–´ê°€ë³´ê² ìŠµë‹ˆë‹¤. ì–¼êµ´ì„ ëŒ€ê³  ëˆ„ì›Œìˆê±°ë‚˜, ì…ìˆ ì„ ì›€ì§ì´ê±°ë‚˜, ì¼ë°˜ì ì¸ ì•ˆë©´ ì›€ì§ì„ì„ ìƒê°í•´ë³´ë©´, ì´ëŸ¬í•œ ìš”ì†Œë“¤ë„ ë§¤ìš° ì˜ ë°˜ì˜ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ë°œê²¬í•œ ë°”ë¡œëŠ”, Evolysse ì ¤ì´ ê²½ìŸ ì œí’ˆë“¤ë³´ë‹¤ ì´ëŸ¬í•œ ì••ì¶•ê³¼ ì „ë‹¨ë ¥ì„ í›¨ì”¬ ë” ì˜ ê²¬ë””ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê¶ê·¹ì ìœ¼ë¡œ ê·€í•˜ì˜ ì§ˆë¬¸ì€ ì´ê²ƒì´ ì„ìƒì—ì„œ ì–´ë–»ê²Œ ë‚˜íƒ€ë‚˜ëŠëƒ í•˜ëŠ” ê²ƒì¸ë°ìš”. ìœ ëŸ½ ì—°êµ¬ì—ì„œ ì´ëŸ¬í•œ ì ¤ì„ ë¹„êµ¬ìˆœì£¼ë¦„(ë‚˜ì†”ë¼ë¹„ì•Œ í´ë“œ)ì— ì£¼ì…í•˜ê³  ëŒ€ì¡°êµ°ì„ ì„¤ì •í–ˆì„ ë•Œ - ì¦‰, í•œìª½ì—ëŠ” ëŒ€ì¡°êµ°ì„ ë‘ì—ˆì„ ë•Œ - ì¢‹ì€ ê²°ê³¼ë¥¼ í™•ì¸í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We found that despite the same amount of gel being used, there always seemed to be more correction with the Evolysse technology. And in the US study, it was a bigger study. Once again, both gels were tested split base. And what we found in the case of form, despite the fact that the same amount of gel was used, there was always more correction at all time points. So that implies kind of longer duration and higher efficacy at all the time points. Certainly statistically we saw a statistical difference at every one of those time points. And then when we looked at smooth, the interesting thing was the control actually used 20% more volume.</td><td>ë™ì¼í•œ ì–‘ì˜ ì ¤ì´ ì‚¬ìš©ë˜ì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , Evolysse ê¸°ìˆ ì„ ì‚¬ìš©í–ˆì„ ë•Œ í•­ìƒ ë” ë§ì€ êµì • íš¨ê³¼ê°€ ë‚˜íƒ€ë‚˜ëŠ” ê²ƒì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ì§„í–‰ëœ ë” í° ê·œëª¨ì˜ ì—°êµ¬ì—ì„œë„, ë‘ ì ¤ ëª¨ë‘ ë¶„í•  ê¸°ì¤€ìœ¼ë¡œ í…ŒìŠ¤íŠ¸ë˜ì—ˆìŠµë‹ˆë‹¤. Form ì œí’ˆì˜ ê²½ìš°, ë™ì¼í•œ ì–‘ì˜ ì ¤ì´ ì‚¬ìš©ë˜ì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  ëª¨ë“  ì¸¡ì • ì‹œì ì—ì„œ í•­ìƒ ë” ë§ì€ êµì • íš¨ê³¼ê°€ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì´ëŠ” ë” ê¸´ ì§€ì† ê¸°ê°„ê³¼ ëª¨ë“  ì¸¡ì • ì‹œì ì—ì„œ ë” ë†’ì€ íš¨ëŠ¥ì„ ì‹œì‚¬í•©ë‹ˆë‹¤. í†µê³„ì ìœ¼ë¡œë„ ëª¨ë“  ì¸¡ì • ì‹œì ì—ì„œ ìœ ì˜ë¯¸í•œ ì°¨ì´ê°€ ê´€ì°°ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Smooth ì œí’ˆì„ ì‚´í´ë³´ì•˜ì„ ë•Œ í¥ë¯¸ë¡œìš´ ì ì€ ëŒ€ì¡°êµ°ì—ì„œ ì‹¤ì œë¡œ 20% ë” ë§ì€ ìš©ëŸ‰ì´ ì‚¬ìš©ë˜ì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And despite that, there always seemed to be more correction, at least on an absolute basis. And it still hit statistical significance. It's a nine months. So in other words, we do a better job of preserving that ha. It seems to withstand kind of rigor testing on the benchtop and in human data, we seem to see really good performance against the control and seems to last longer. Operator<br><br>Thank you. Our next question comes from the line of Navann Ty with BNP Paribas. Please proceed. Navann Ty<br><br>Hi. Thanks for taking my questions. I had one on the weight loss label. Interested? How were you able to add that claim versus peers and do you expect competitors to follow?</td><td>Korean translation:<br><br>ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³ , ì ˆëŒ€ì ì¸ ê¸°ì¤€ìœ¼ë¡œ ë³¼ ë•Œ ë” ë§ì€ êµì •ì´ ìˆëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ì „íˆ í†µê³„ì ìœ¼ë¡œ ìœ ì˜ë¯¸í•œ ìˆ˜ì¤€ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. 9ê°œì›” ê¸°ê°„ì…ë‹ˆë‹¤. ë‹¤ì‹œ ë§í•´ì„œ, ì €í¬ëŠ” ê·¸ íš¨ê³¼ë¥¼ ë” ì˜ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤í—˜ì‹¤ ë²¤ì¹˜ í…ŒìŠ¤íŠ¸ì—ì„œì˜ ì—„ê²©í•œ ê²€ì¦ì„ ê²¬ëŒë‚´ëŠ” ê²ƒìœ¼ë¡œ ë³´ì´ë©°, ì¸ì²´ ë°ì´í„°ì—ì„œë„ ëŒ€ì¡°êµ° ëŒ€ë¹„ ë§¤ìš° ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ë” ì˜¤ë˜ ì§€ì†ë˜ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì§„í–‰ì<br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ë‹¤ìŒ ì§ˆë¬¸ì€ BNP íŒŒë¦¬ë°”ì˜ ë‚˜ë°˜ í‹° ì—°êµ¬ì›ë‹˜ê»˜ì„œ í•˜ì‹œê² ìŠµë‹ˆë‹¤. ë‚˜ë°˜ í‹°<br><br>ì•ˆë…•í•˜ì„¸ìš”. ì§ˆë¬¸ì— ë‹µë³€í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì²´ì¤‘ ê°ëŸ‰ ë¼ë²¨ì— ëŒ€í•´ ì§ˆë¬¸ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. í¥ë¯¸ë¡œìš´ ì ì€, ê²½ìŸì‚¬ë“¤ê³¼ ë¹„êµí–ˆì„ ë•Œ ì–´ë–»ê²Œ ì´ íš¨ëŠ¥ í‘œì‹œë¥¼ ì¶”ê°€í•  ìˆ˜ ìˆì—ˆëŠ”ì§€, ê·¸ë¦¬ê³  ê²½ìŸì‚¬ë“¤ë„ ì´ë¥¼ ë”°ë¥¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>And then a second question more Generally on the Q4 market shares, how did they move across the category and did you maybe benefit from [indiscernible] redesigning their loyalty program? Thank you. David Moatazedi<br><br>Sure. On the patient labeling, obviously there's negotiation that goes on with the agency. So tip our hats to our R&D group. And in terms of, you know, others to follow, obviously I can't speak for others, but I guess it's a form of flattery if people copy what we did. Rui Avelar<br><br>And on the share gain, we have consistently looked at it over a full year period. And over the last several years, you've seen we've continued to gain two share points each year.</td><td>4ë¶„ê¸° ì‹œì¥ ì ìœ ìœ¨ì— ëŒ€í•œ ë‘ ë²ˆì§¸ ì§ˆë¬¸ê³¼ ê´€ë ¨í•˜ì—¬, ì¹´í…Œê³ ë¦¬ ì „ë°˜ì— ê±¸ì³ ì–´ë–»ê²Œ ë³€í™”í–ˆìœ¼ë©°, [ì•Œì•„ë“¤ì„ ìˆ˜ ì—†ìŒ] ë¡œì—´í‹° í”„ë¡œê·¸ë¨ ì¬ì„¤ê³„ë¡œë¶€í„° í˜œíƒì„ ë°›ìœ¼ì…¨ëŠ”ì§€ìš”? David Moatazedi<br><br>ë„¤. í™˜ì ë¼ë²¨ë§ê³¼ ê´€ë ¨í•´ì„œëŠ” ë‹¹ì—°íˆ ê·œì œ ë‹¹êµ­ê³¼ì˜ í˜‘ìƒì´ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ ì ì—ì„œ ìš°ë¦¬ R&D íŒ€ì— ê°ì‚¬ë¥¼ í‘œí•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ë‹¤ë¥¸ ì—…ì²´ë“¤ì˜ í›„ì† ì¡°ì¹˜ì— ëŒ€í•´ì„œëŠ” ì œê°€ ì–¸ê¸‰í•˜ê¸°ëŠ” ì–´ë µì§€ë§Œ, ë§Œì•½ ê·¸ë“¤ì´ ìš°ë¦¬ì˜ ë°©ì‹ì„ ëª¨ë°©í•œë‹¤ë©´ ê·¸ê²ƒì€ ì¼ì¢…ì˜ ì°¬ì‚¬ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. Rui Avelar<br><br>ì‹œì¥ ì ìœ ìœ¨ ì¦ê°€ì™€ ê´€ë ¨í•´ì„œëŠ”, ìš°ë¦¬ëŠ” ì§€ì†ì ìœ¼ë¡œ ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ì´ë¥¼ ê²€í† í•´ì™”ìŠµë‹ˆë‹¤. ì§€ë‚œ ìˆ˜ë…„ê°„ ë§¤ë…„ 2%í¬ì¸íŠ¸ì”© ì‹œì¥ ì ìœ ìœ¨ì´ ê¾¸ì¤€íˆ ì¦ê°€í•˜ëŠ” ê²ƒì„ ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And of course, in 2024, we didn't expect to gain two points and we did. So this brand just continues to perform. And I give a lot of credit to the team. I think we have an excellent sales organization, great leadership throughout, and a marketing team that's delivered some very unique marketing programs to drive the growth in the category. And what you're seeing is the market's rewarding us. Here we are six years into the category in May, and I think we're the stable hand in the space. The value proposition we brought in focused on cash pay and reinvesting back into these practices is resonating with clinics. And as they're finding out from their peers that they there's value we bring back.</td><td>ë¬¼ë¡  2024ë…„ì—ëŠ” 2í¬ì¸íŠ¸ë¥¼ ì–»ì„ ê²ƒì´ë¼ê³  ì˜ˆìƒí•˜ì§€ ëª»í–ˆëŠ”ë° ì‹¤ì œë¡œ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ ë¸Œëœë“œëŠ” ê³„ì†í•´ì„œ ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ íŒ€ì˜ ê³µë¡œê°€ í½ë‹ˆë‹¤. ìš°ìˆ˜í•œ ì˜ì—… ì¡°ì§ê³¼ ì „ë°˜ì ìœ¼ë¡œ íƒì›”í•œ ë¦¬ë”ì‹­, ê·¸ë¦¬ê³  ì¹´í…Œê³ ë¦¬ì˜ ì„±ì¥ì„ ì´ëŒì–´ë‚´ê¸° ìœ„í•´ ë§¤ìš° ë…íŠ¹í•œ ë§ˆì¼€íŒ… í”„ë¡œê·¸ë¨ë“¤ì„ ì„ ë³´ì¸ ë§ˆì¼€íŒ… íŒ€ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë³´ì‹œë‹¤ì‹œí”¼ ì‹œì¥ì´ ìš°ë¦¬ì—ê²Œ ë³´ë‹µí•˜ê³  ìˆìŠµë‹ˆë‹¤. 5ì›”ì´ë©´ ì´ ì¹´í…Œê³ ë¦¬ì— ì§„ì¶œí•œ ì§€ 6ë…„ì´ ë˜ëŠ”ë°, ìš°ë¦¬ê°€ ì´ ë¶„ì•¼ì—ì„œ ì•ˆì •ì ì¸ ì£¼ìë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í˜„ê¸ˆ ê²°ì œì— ì¤‘ì ì„ ë‘ê³  ì´ëŸ¬í•œ ì‚¬ì—…ì²´ë“¤ì— ì¬íˆ¬ìí•˜ëŠ” ìš°ë¦¬ì˜ ê°€ì¹˜ ì œì•ˆì´ í´ë¦¬ë‹‰ë“¤ì—ê²Œ í˜¸ì‘ì„ ì–»ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ í´ë¦¬ë‹‰ë“¤ì´ ë™ì¢… ì—…ê³„ë¡œë¶€í„° ìš°ë¦¬ê°€ ì œê³µí•˜ëŠ” ê°€ì¹˜ì— ëŒ€í•´ ì•Œê²Œ ë˜ë©´ì„œ ë”ìš± ê¸ì •ì ì¸ ë°˜ì‘ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>When you partner with us, I think there's a greater interest in us becoming that partner. Now, in all fairness, we've had limited ability to extend that partnership with one product. And now with Evolysse, that opens up another opportunity for us to have a deeper partnership with these practices around the same cash pay platform that's differentiated versus the market set. So look, we certainly gained share in the fourth quarter. There's no doubt about that. On the full year, we're now approaching 14% share, which sits above the share we had guided for in 2028. Just as a point of reference, we're just really pleased with the way we're exiting. But we see a lot of momentum going forward.</td><td>ì €í¬ì™€ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºìœ¼ì‹¤ ë•Œ, ì €í¬ê°€ íŒŒíŠ¸ë„ˆê°€ ë˜ëŠ” ê²ƒì— ëŒ€í•œ ê´€ì‹¬ì´ ë”ìš± ì»¤ì§„ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë¬¼ë¡ , ì§€ê¸ˆê¹Œì§€ëŠ” ë‹¨ì¼ ì œí’ˆìœ¼ë¡œ ì¸í•´ íŒŒíŠ¸ë„ˆì‹­ì„ í™•ì¥í•˜ëŠ” ë° ì œí•œì´ ìˆì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ì œ Evolysseë¥¼ í†µí•´, ì‹œì¥ê³¼ ì°¨ë³„í™”ëœ ë™ì¼í•œ ìê¸°ë¶€ë‹´ í”Œë«í¼ì„ ê¸°ë°˜ìœ¼ë¡œ ì´ëŸ¬í•œ ì˜ë£Œê¸°ê´€ë“¤ê³¼ ë” ê¹Šì€ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºì„ ìˆ˜ ìˆëŠ” ìƒˆë¡œìš´ ê¸°íšŒê°€ ìƒê²¼ìŠµë‹ˆë‹¤. <br><br>4ë¶„ê¸°ì— ì €í¬ê°€ ì‹œì¥ì ìœ ìœ¨ì„ í™•ì‹¤íˆ ë†’ì˜€ë‹¤ëŠ” ê²ƒì€ ë¶„ëª…í•œ ì‚¬ì‹¤ì…ë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ë³´ë©´, í˜„ì¬ ì €í¬ì˜ ì‹œì¥ì ìœ ìœ¨ì€ 14%ì— ê·¼ì ‘í•˜ê³  ìˆëŠ”ë°, ì´ëŠ” 2028ë…„ì— ë‹¬ì„±í•˜ê² ë‹¤ê³  ì œì‹œí–ˆë˜ ëª©í‘œì¹˜ë¥¼ ì´ë¯¸ ìƒíšŒí•˜ëŠ” ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì°¸ê³ ë¡œ ë§ì”€ë“œë¦¬ìë©´, ì €í¬ëŠ” í˜„ì¬ì˜ ì‹¤ì  ë§ˆê°ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•ìœ¼ë¡œë„ ìƒë‹¹í•œ ì„±ì¥ ëª¨ë©˜í…€ì´ ì´ì–´ì§ˆ ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We're only in half the clinics today. And despite that we have a 14% overall share. Approaching 14%. We still have another 50% of the market that is not working with Evolus today. And we think Evolus gives us the ability to go wider over time into the rest of the market, but also deeper within our existing customers that want to partner with us to a greater degree. So this is a really important inflection point year for the company to deliver. Operator<br><br>Thank you. Our next question comes from the line of UVIR with Mizuho securities. Please proceed. Unidenified Analyst<br><br>Hey, thanks for taking our question. This is Charles on for OI. So I guess kind of outside of the U.S.</td><td>í˜„ì¬ ì €í¬ëŠ” ì „ì²´ í´ë¦¬ë‹‰ì˜ ì ˆë°˜ì—ë§Œ ì§„ì¶œí•´ ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  ì „ì²´ ì‹œì¥ì ìœ ìœ¨ì´ 14%ì— ê·¼ì ‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•„ì§ Evolusì™€ ê±°ë˜í•˜ì§€ ì•ŠëŠ” ì‹œì¥ì˜ 50%ê°€ ë‚¨ì•„ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. ì €í¬ëŠ” Evolusë¥¼ í†µí•´ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ë‚˜ë¨¸ì§€ ì‹œì¥ìœ¼ë¡œ í™•ì¥í•  ìˆ˜ ìˆì„ ë¿ë§Œ ì•„ë‹ˆë¼, ì €í¬ì™€ ë” ê¸´ë°€í•œ íŒŒíŠ¸ë„ˆì‹­ì„ ì›í•˜ëŠ” ê¸°ì¡´ ê³ ê°ë“¤ê³¼ì˜ ê´€ê³„ë„ ë”ìš± ê°•í™”í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì˜¬í•´ëŠ” íšŒì‚¬ê°€ ì„±ê³¼ë¥¼ ë‹¬ì„±í•´ì•¼ í•˜ëŠ” ë§¤ìš° ì¤‘ìš”í•œ ë³€ê³¡ì ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì§„í–‰ì ë§ì”€ì…ë‹ˆë‹¤.<br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ë‹¤ìŒ ì§ˆë¬¸ì€ Mizuho Securitiesì˜ UVIR ì¸¡ì—ì„œ í•˜ì‹œê² ìŠµë‹ˆë‹¤. ë§ì”€í•´ ì£¼ì‹­ì‹œì˜¤. ì‹ ì›ë¯¸ìƒì˜ ì• ë„ë¦¬ìŠ¤íŠ¸ì…ë‹ˆë‹¤.<br><br>ì•ˆë…•í•˜ì„¸ìš”, ì§ˆë¬¸ì— ë‹µë³€í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. OIë¥¼ ëŒ€ì‹ í•´ì„œ Charlesì…ë‹ˆë‹¤. ë¯¸êµ­ ì´ì™¸ ì§€ì—­ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê³ ì í•˜ëŠ”ë°ìš”.</td></tr>
<tr><td>we saw that, I guess in 2025, should we expect service revenues to be around $2 to $3 million? Then also can you explain why we saw negative service revenues in 4Q24? And then also the comments about new CVA revenues growing in 2025. Is that kind of a proportional growth or is that just kind of a year over year growth? Comment? Thank you. Sandra Beaver<br><br>Thanks for the question, Charles. As it relates to service revenue, it's generally a relatively stable revenue stream for us. I wouldn't expect it to grow meaningfully comparative to prior periods. It is isolated to one account and one contract in Canada. The remainder of our revenue is all booked as product revenue.</td><td>ì°°ìŠ¤ì˜ ì§ˆë¬¸ì— ë‹µë³€ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì„œë¹„ìŠ¤ ë§¤ì¶œê³¼ ê´€ë ¨í•˜ì—¬, ì´ëŠ” ì¼ë°˜ì ìœ¼ë¡œ ë‹¹ì‚¬ì— ìˆì–´ ë¹„êµì  ì•ˆì •ì ì¸ ìˆ˜ìµì›ì…ë‹ˆë‹¤. ì´ì „ ê¸°ê°„ê³¼ ë¹„êµí–ˆì„ ë•Œ í° í­ì˜ ì„±ì¥ì€ ê¸°ëŒ€í•˜ê¸° ì–´ë ¤ìš¸ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì´ëŠ” ìºë‚˜ë‹¤ì˜ í•œ ê³ ê°ì‚¬ì™€ì˜ ë‹¨ì¼ ê³„ì•½ì— êµ­í•œë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë‚˜ë¨¸ì§€ ë§¤ì¶œì€ ëª¨ë‘ ì œí’ˆ ë§¤ì¶œë¡œ ê³„ìƒë˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>Note: The translation maintains the professional tone of the CFO's response while accurately conveying the financial information. Key financial terms like "service revenue" (ì„œë¹„ìŠ¤ ë§¤ì¶œ), "revenue stream" (ìˆ˜ìµì›), and "product revenue" (ì œí’ˆ ë§¤ì¶œ) are appropriately translated using standard Korean financial terminology. The response remains clear and concise, suitable for a Korean business audience.</td></tr>
<tr><td>So I wouldn't expect material changes there. And we do see just some timing of when we have those revenues hit. Yeah. As it relates to new CEVA, really you're looking at the international market for all of that new CEVA growth. And as we've stated a few times, we expect that market to meaningfully outpace our growth in the us. So it's still coming over a relatively small base given that we've only recently completed the launches in the countries we need to deliver our long term guidance with no CEVA. So we do have that opportunity to continue to lap around those launches we launched in Australia and Spain.</td><td>ì‹ ê·œ CEVAì™€ ê´€ë ¨í•´ì„œëŠ”, ëª¨ë“  ì„±ì¥ì´ êµ­ì œ ì‹œì¥ì—ì„œ ì´ë£¨ì–´ì§ˆ ê²ƒìœ¼ë¡œ ì „ë§ë©ë‹ˆë‹¤. ì•ì„œ ì—¬ëŸ¬ ì°¨ë¡€ ì–¸ê¸‰í–ˆë“¯ì´, í•´ë‹¹ ì‹œì¥ì˜ ì„±ì¥ë¥ ì€ ë¯¸êµ­ ì‹œì¥ ì„±ì¥ë¥ ì„ í¬ê²Œ ìƒíšŒí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì¥ê¸° ê°€ì´ë˜ìŠ¤ ë‹¬ì„±ì— í•„ìš”í•œ êµ­ê°€ë“¤ì—ì„œì˜ ì¶œì‹œê°€ ìµœê·¼ì—ì•¼ ì™„ë£Œë˜ì—ˆê¸° ë•Œë¬¸ì—, ì•„ì§ì€ ìƒëŒ€ì ìœ¼ë¡œ ì‘ì€ ê¸°ë°˜ì—ì„œ ì‹œì‘í•˜ëŠ” ë‹¨ê³„ì…ë‹ˆë‹¤. ë”°ë¼ì„œ í˜¸ì£¼ì™€ ìŠ¤í˜ì¸ì—ì„œì˜ ì¶œì‹œë¥¼ ê¸°ì ìœ¼ë¡œ ì§€ì†ì ì¸ ì„±ì¥ ê¸°íšŒê°€ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤.<br><br>ê·¸ë˜ì„œ ì—¬ê¸°ì—ì„œ í° ë³€í™”ëŠ” ì˜ˆìƒí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë‹¤ë§Œ ë§¤ì¶œ ì¸ì‹ ì‹œì ê³¼ ê´€ë ¨ëœ ì¼ë¶€ íƒ€ì´ë° ì´ìŠˆëŠ” ìˆì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And we've been continuing to see the contribution of the international revenue streams grow and we expect it to continue to grow. So this year we were approximately 5% of our revenue coming from international and that percentage should continue to increase. So it will grow from a small base meaningfully faster than the US grows, but still a relatively small contributor to the overall portfolio. Operator<br><br>Our next question comes to the line of Doug Tsao with H.C. Wainwright. Please proceed with your question. Doug Tsao<br><br>Hi, good afternoon and thanks for taking the questions. Just a couple for me. I'm just curious. In terms of the launch of Smooth and form.</td><td>í•´ì™¸ ë§¤ì¶œ ê¸°ì—¬ë„ê°€ ì§€ì†ì ìœ¼ë¡œ ì¦ê°€í•˜ëŠ” ê²ƒì„ í™•ì¸í•˜ê³  ìˆìœ¼ë©°, ì•ìœ¼ë¡œë„ ì´ëŸ¬í•œ ì„±ì¥ì„¸ê°€ ì´ì–´ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì˜¬í•´ í•´ì™¸ ë§¤ì¶œì€ ì „ì²´ ë§¤ì¶œì˜ ì•½ 5%ë¥¼ ì°¨ì§€í–ˆìœ¼ë©°, ì´ ë¹„ì¤‘ì€ ê³„ì†í•´ì„œ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì „ë§ë©ë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥ ëŒ€ë¹„ ìƒëŒ€ì ìœ¼ë¡œ ì‘ì€ ê¸°ë°˜ì—ì„œ ë” ë¹ ë¥¸ ì„±ì¥ì„¸ë¥¼ ë³´ì¼ ê²ƒì´ë‚˜, ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ ì°¨ì§€í•˜ëŠ” ë¹„ì¤‘ì€ ì—¬ì „íˆ ë¹„êµì  ì‘ì„ ê²ƒì…ë‹ˆë‹¤.<br><br>ì§„í–‰ì: ë‹¤ìŒ ì§ˆë¬¸ì€ H.C. ì›¨ì¸ë¼ì´íŠ¸ì˜ ë”ê·¸ ì°¨ì˜¤ ë‹˜ê»˜ì„œ í•˜ì‹œê² ìŠµë‹ˆë‹¤. ì§ˆë¬¸í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>ë”ê·¸ ì°¨ì˜¤: ì•ˆë…•í•˜ì„¸ìš”, ì˜¤í›„ ì¸ì‚¬ë“œë¦½ë‹ˆë‹¤. ì§ˆë¬¸ì— ë‹µë³€í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì œê°€ ëª‡ ê°€ì§€ ì—¬ì­¤ë³´ê³  ì‹¶ì€ ê²ƒì´ ìˆìŠµë‹ˆë‹¤. Smoothì™€ formì˜ ì¶œì‹œì™€ ê´€ë ¨í•˜ì—¬ ê¶ê¸ˆí•œ ì ì´ ìˆëŠ”ë°ìš”.</td></tr>
<tr><td>I'm just curious to understand a little bit about the process for accounts to start using it. You know, is it just sort of a question of expressing interest or are you sort of prioritizing certain accounts? And then I was just curious, now that you are adding the evolution, do you anticipate making changes to any of your customer loyalty programs in any way? Thank you. David Moatazedi<br><br>Great. Thanks for the question, Doug. I think a couple things on the Evolysse launch. The first is we're going to disclose the details of our launch plans at our national sales meeting at the end of March and at that time the specifics will become clear to the market.</td><td>ê³„ì •ë“¤ì´ ì´ë¥¼ ì‚¬ìš©í•˜ê¸° ì‹œì‘í•˜ëŠ” ê³¼ì •ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤. ë‹¨ìˆœíˆ ê´€ì‹¬ì„ í‘œëª…í•˜ëŠ” ê²ƒë§Œìœ¼ë¡œ ì¶©ë¶„í•œì§€, ì•„ë‹ˆë©´ íŠ¹ì • ê³„ì •ë“¤ì— ìš°ì„ ìˆœìœ„ë¥¼ ë‘ê³  ê³„ì‹œëŠ”ì§€ìš”? ê·¸ë¦¬ê³  ì´ë²ˆì— ì—ë³¼ë¦¬ìŠ¤(Evolysse)ë¥¼ ì¶”ê°€í•˜ì‹œë©´ì„œ, ê³ ê° ë¡œì—´í‹° í”„ë¡œê·¸ë¨ì— ì–´ë–¤ ë³€í™”ë¥¼ ì£¼ì‹¤ ê³„íšì´ ìˆìœ¼ì‹ ì§€ë„ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. David Moatazedi<br><br>ë„¤, Dougë‹˜ì˜ ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì—ë³¼ë¦¬ìŠ¤ ì¶œì‹œì™€ ê´€ë ¨í•´ì„œ ëª‡ ê°€ì§€ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ì„ , 3ì›” ë§ì— ìˆì„ ì „êµ­ ì˜ì—…íšŒì˜ì—ì„œ ì¶œì‹œ ê³„íšì˜ ì„¸ë¶€ì‚¬í•­ì„ ê³µê°œí•  ì˜ˆì •ì´ë©°, ê·¸ ì‹œì ì— ì‹œì¥ì— êµ¬ì²´ì ì¸ ë‚´ìš©ì´ ëª…í™•íˆ ì „ë‹¬ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>However, as you know, we built up an entirely new educational platform called Evolus Academy last year and individuals heading that up has built out not only our executive council but founding faculty that are going to be trained and will be training accounts in the second quarter. It's a sizable group that will complement a very large medical affairs clinician team that last year conducted nearly 10,000 trainings. So when you couple those two ideas together and you think about our training capabilities for the full year of 2025, we're well over 12, 13,000 accounts that we'll be able to train over the course of the year.</td><td>ì•„ì‹œë‹¤ì‹œí”¼, ì €í¬ëŠ” ì‘ë…„ì— Evolus Academyë¼ëŠ” ì™„ì „íˆ ìƒˆë¡œìš´ êµìœ¡ í”Œë«í¼ì„ êµ¬ì¶•í–ˆìœ¼ë©°, ì´ë¥¼ ì£¼ë„í•˜ëŠ” ì¸ë ¥ë“¤ì´ ì„ì› ìœ„ì›íšŒë¿ë§Œ ì•„ë‹ˆë¼ 2ë¶„ê¸°ì— ê³„ì •ë“¤ì„ êµìœ¡í•˜ê²Œ ë  ì°½ë¦½ êµìˆ˜ì§„ì„ êµ¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì‘ë…„ì— ê±°ì˜ 10,000ê±´ì˜ êµìœ¡ì„ ì‹¤ì‹œí•œ ëŒ€ê·œëª¨ ë©”ë””ì»¬ ì–´í˜ì–´ìŠ¤ ì„ìƒì˜ íŒ€ì„ ë³´ì™„í•˜ëŠ” ìƒë‹¹í•œ ê·œëª¨ì˜ ê·¸ë£¹ì…ë‹ˆë‹¤. ì´ ë‘ ê°€ì§€ë¥¼ í•¨ê»˜ ê³ ë ¤í•˜ê³  2025ë…„ ì—°ê°„ êµìœ¡ ì—­ëŸ‰ì„ ìƒê°í•´ë³´ë©´, ì—°ê°„ 12,000~13,000ê°œ ì´ìƒì˜ ê³„ì •ì— ëŒ€í•´ êµìœ¡ì„ ì œê³µí•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.<br><br>Note: I preserved key terms like "Evolus Academy", "medical affairs" and maintained the professional, confident tone while ensuring the Korean translation flows naturally and is easily understood by Korean investors.</td></tr>
<tr><td>So that gives us a significant amount of training power which to answer your question, doesn't require us to prioritize just our top tier accounts, but allows us to go broad fast with these customers. So I think we're going to start in the second quarter doing the training, but we anticipate that in a very short period of time we can get to the majority of our customer base that is actively using both toxins and fillers in a very quick period of time. So we're really pleased with that. And then lastly on the loyalty program, the Evolus rewards, the co-branded media benefits begin immediately in the second quarter.</td><td>ì´ëŠ” ì €í¬ì—ê²Œ ìƒë‹¹í•œ êµìœ¡ ì—­ëŸ‰ì„ ì œê³µí•˜ë©°, ê·€í•˜ì˜ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ìë©´, ìµœìƒìœ„ ë“±ê¸‰ ê³ ê°ë“¤ë§Œì„ ìš°ì„ ì‹œí•  í•„ìš” ì—†ì´ ê´‘ë²”ìœ„í•œ ê³ ê°ì¸µì— ì‹ ì†í•˜ê²Œ ë‹¤ê°€ê°ˆ ìˆ˜ ìˆê²Œ í•´ì¤ë‹ˆë‹¤. 2ë¶„ê¸°ë¶€í„° êµìœ¡ì„ ì‹œì‘í•  ì˜ˆì •ì´ì§€ë§Œ, ë§¤ìš° ì§§ì€ ê¸°ê°„ ë‚´ì— í†¡ì‹ ê³¼ í•„ëŸ¬ë¥¼ ì ê·¹ì ìœ¼ë¡œ ì‚¬ìš©í•˜ëŠ” ëŒ€ë‹¤ìˆ˜ì˜ ê³ ê° ê¸°ë°˜ì— ë„ë‹¬í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ ì ì— ëŒ€í•´ ë§¤ìš° ê³ ë¬´ì ìœ¼ë¡œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ë¡œì—´í‹° í”„ë¡œê·¸ë¨ì¸ Evolus Rewardsì™€ ê´€ë ¨í•˜ì—¬, ê³µë™ ë¸Œëœë“œ ë¯¸ë””ì–´ í˜œíƒì€ 2ë¶„ê¸°ë¶€í„° ì¦‰ì‹œ ì‹œì‘ë©ë‹ˆë‹¤.<br><br>Note: I preserved key terms like "í†¡ì‹ "(toxin), "í•„ëŸ¬"(filler), "Evolus Rewards" while maintaining a professional, business-appropriate tone that would be familiar to Korean investors and financial professionals.</td></tr>
<tr><td>As accounts buy up, they'll earn their dollars on both Jabot and Evolysse and we plan on introducing consumer rewards shortly thereafter so that consumers that earn Jeuveau can also earn savings on Evolus and potentially considering an option of offering benefits if you get both products during the same treatment. So that'll be following shortly after we launch in the US the consumer rewards benefit. We want to prioritize the first few months into the launch to education and training and experience with the product. And we want to have the rewards program for the consumer up and live before we enter the third quarter. Operator<br><br>Okay, great. Thank you so much. Thank you.</td><td>ì˜ë£Œê¸°ê´€ë“¤ì´ êµ¬ë§¤ë¥¼ ëŠ˜ë¦¬ë©´ì„œ Jabotê³¼ Evolysse ëª¨ë‘ì—ì„œ ìˆ˜ìµì„ ì°½ì¶œí•˜ê²Œ ë  ê²ƒì´ë©°, ì´í›„ ê³§ ì†Œë¹„ì ë¦¬ì›Œë“œ í”„ë¡œê·¸ë¨ì„ ë„ì…í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ Jeuveauë¥¼ ì‚¬ìš©í•˜ëŠ” ì†Œë¹„ìë“¤ì´ Evolusì—ì„œë„ í• ì¸ í˜œíƒì„ ë°›ì„ ìˆ˜ ìˆê²Œ ë˜ë©°, ë™ì¼ ì‹œìˆ ì—ì„œ ë‘ ì œí’ˆì„ ëª¨ë‘ ì‚¬ìš©í•  ê²½ìš° ì¶”ê°€ í˜œíƒì„ ì œê³µí•˜ëŠ” ë°©ì•ˆë„ ê²€í†  ì¤‘ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì†Œë¹„ì ë¦¬ì›Œë“œ í˜œíƒì€ ë¯¸êµ­ ì¶œì‹œ ì§í›„ì— ì‹œí–‰ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì¶œì‹œ í›„ ì²« ëª‡ ë‹¬ ë™ì•ˆì€ ì œí’ˆ êµìœ¡ê³¼ íŠ¸ë ˆì´ë‹, ê·¸ë¦¬ê³  ì œí’ˆ ê²½í—˜ ì¶•ì ì— ìš°ì„ ìˆœìœ„ë¥¼ ë‘ê³ ì í•©ë‹ˆë‹¤. 3ë¶„ê¸° ì§„ì… ì „ì—ëŠ” ì†Œë¹„ì ë¦¬ì›Œë“œ í”„ë¡œê·¸ë¨ì„ êµ¬ì¶•í•˜ì—¬ ìš´ì˜í•  ê³„íšì…ë‹ˆë‹¤. ì§„í–‰ìë‹˜.<br><br>ë„¤, ì¢‹ìŠµë‹ˆë‹¤. ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Our next question comes from the line of Serge Belanger with Needham & Company. Please proceed. Serge Belanger<br><br>Hi, good afternoon. First question is regarding new accounts. I think you added just a shade under 3,000 new accounts this year, similar to last year. So now that you're over 50% of the overall US total accounts, just curious how you think that number could look like for 2025, given that you're over 50% and you're launching Evolus. And then secondly on Evolysse, sounds like the COLD-X technology lends some differentiation to Evolase versus other fillers. But just curious, in terms of the training and the injection procedures, is there anything different on that front? Thanks.</td><td>Needham & Companyì˜ Serge Belanger ë¼ì¸ì—ì„œ ë‹¤ìŒ ì§ˆë¬¸ì´ ë“¤ì–´ì™”ìŠµë‹ˆë‹¤. ì§„í–‰í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. Serge Belanger<br><br>ì•ˆë…•í•˜ì„¸ìš”, ì¢‹ì€ ì˜¤í›„ì…ë‹ˆë‹¤. ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ ì‹ ê·œ ê³„ì •ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì˜¬í•´ ì•½ 3,000ê°œì˜ ì‹ ê·œ ê³„ì •ì„ ì¶”ê°€í•˜ì…¨ëŠ”ë°, ì´ëŠ” ì‘ë…„ê³¼ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì…ë‹ˆë‹¤. í˜„ì¬ ë¯¸êµ­ ì „ì²´ ê³„ì •ì˜ 50% ì´ìƒì„ í™•ë³´í•˜ì‹  ìƒí™©ì—ì„œ, Evolus ì¶œì‹œë¥¼ ê³ ë ¤í•  ë•Œ 2025ë…„ì—ëŠ” ì´ ìˆ˜ì¹˜ê°€ ì–´ë–»ê²Œ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. <br><br>ë‘ ë²ˆì§¸ë¡œ Evolysseì— ê´€í•´ì„œì¸ë°ìš”, COLD-X ê¸°ìˆ ì´ ë‹¤ë¥¸ í•„ëŸ¬ë“¤ê³¼ ì°¨ë³„í™”ë˜ëŠ” ìš”ì†Œë¥¼ ì œê³µí•˜ëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ êµìœ¡ê³¼ ì£¼ì… ì ˆì°¨ ì¸¡ë©´ì—ì„œ ë‹¤ë¥¸ ì ì´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>David Moatazedi<br><br>Sure. I'll take the first part and I'll turn it over to Rui, take the second. I think historically, Serge, as you know, we said we expected to add roughly 500 new accounts per quarter. We've been doing that consistently now for multiple years. With the launch of Evolysse, we're going to prioritize getting to our existing customers around education and training on the new product rather than opening new accounts. So you should expect a step down in new accounts as a result of that. And so we don't have a guide, so to speak, of roughly 500 new accounts a quarter this year for that reason. But then once we transition into 2026, we'll revisit that.</td><td>David Moatazedi<br><br>ë„¤, ì²« ë²ˆì§¸ ë¶€ë¶„ì€ ì œê°€ ë‹µë³€ ë“œë¦¬ê³ , ë‘ ë²ˆì§¸ ë¶€ë¶„ì€ Ruiì—ê²Œ ë„˜ê¸°ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. Sergeë‹˜ë„ ì•„ì‹œë‹¤ì‹œí”¼, ìš°ë¦¬ëŠ” ì—­ì‚¬ì ìœ¼ë¡œ ë¶„ê¸°ë‹¹ ì•½ 500ê°œì˜ ì‹ ê·œ ê±°ë˜ì²˜ë¥¼ í™•ë³´í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí–ˆê³ , ì§€ë‚œ ìˆ˜ë…„ê°„ ì´ë¥¼ ê¾¸ì¤€íˆ ë‹¬ì„±í•´ ì™”ìŠµë‹ˆë‹¤. Evolysse ì¶œì‹œì™€ í•¨ê»˜, ì‹ ê·œ ê±°ë˜ì²˜ ê°œì„¤ë³´ë‹¤ëŠ” ê¸°ì¡´ ê³ ê°ë“¤ì— ëŒ€í•œ ì‹ ì œí’ˆ êµìœ¡ê³¼ íŠ¸ë ˆì´ë‹ì— ìš°ì„ ìˆœìœ„ë¥¼ ë‘˜ ì˜ˆì •ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ë¡œ ì¸í•´ ì‹ ê·œ ê±°ë˜ì²˜ ìˆ˜ê°€ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì…”ì•¼ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì˜¬í•´ëŠ” ë¶„ê¸°ë‹¹ ì•½ 500ê°œì˜ ì‹ ê·œ ê±°ë˜ì²˜ í™•ë³´ë¼ëŠ” ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ì— ì§„ì…í•˜ë©´ì„œ ì´ ë¶€ë¶„ì„ ë‹¤ì‹œ ê²€í† í•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>But we've asked our team to prioritize ensuring that our existing account have the opportunity to try Evolysse, but where at the same time, we're getting a lot of interest from non users of Evolus products to get trained on Jeuveau and Evolysse. And so we're also trying to support them at the same time. Frankly, it's a great problem to have, but we need to continue to ensure that we support our existing customer base. Now I'll let Rui talk a little bit about what's involved in the training of Evolysse relative to other fillers. Rui Avelar<br><br>Sure. So one thing just kind of at a very high level when you look at fillers, some you have to overcorrect because you lose a lot of the free ha gel.</td><td>ë‹¤ë§Œ, ì €í¬ëŠ” ê¸°ì¡´ ê³ ê°ë“¤ì´ Evolysseë¥¼ ì‹œë„í•´ë³¼ ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ìš°ì„ ì ìœ¼ë¡œ ë³´ì¥í•˜ë„ë¡ íŒ€ì— ìš”ì²­í–ˆìŠµë‹ˆë‹¤. ë™ì‹œì— Evolus ì œí’ˆì„ ì‚¬ìš©í•˜ì§€ ì•Šì•˜ë˜ ë§ì€ ì˜ë£Œì§„ë“¤ì´ Jeuveauì™€ Evolysse êµìœ¡ì— ê´€ì‹¬ì„ ë³´ì´ê³  ìˆì–´ ì´ë“¤ë„ ì§€ì›í•˜ê³ ì ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ì´ëŠ” ì¢‹ì€ ê³ ë¯¼ê±°ë¦¬ì…ë‹ˆë‹¤ë§Œ, ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ ê¸°ì¡´ ê³ ê° ê¸°ë°˜ì„ ì§€ì›í•˜ëŠ” ê²ƒì„ ë³´ì¥í•´ì•¼ í•©ë‹ˆë‹¤. ì´ì œ Ruiê°€ ë‹¤ë¥¸ í•„ëŸ¬ë“¤ê³¼ ë¹„êµí•˜ì—¬ Evolysse êµìœ¡ì— ì–´ë–¤ ê²ƒë“¤ì´ í¬í•¨ë˜ëŠ”ì§€ ì„¤ëª…í•´ ë“œë¦¬ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. Rui Avelarì…ë‹ˆë‹¤.<br><br>ë„¤, í•„ëŸ¬ì— ëŒ€í•´ ì•„ì£¼ ê°œê´„ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ìë©´, ì¼ë¶€ í•„ëŸ¬ì˜ ê²½ìš° í”„ë¦¬ HA ì ¤ì´ ë§ì´ ì†Œì‹¤ë˜ê¸° ë•Œë¬¸ì— ê³¼êµì •ì„ í•´ì•¼ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>So you have to train that way. Some fillers you have to under correct, so you want to put in a little bit less because the gel's going to swell over time. What we have found is these gels are really well balanced. And so the training is really to correct to the optimal correction. So when you correct that patient, bring them to where you want them, you do not have to accommodate for gel going away or for swelling. So that's one basic element. The other big element is it's a very forgiving gel. So we have a lot of latitude.</td><td>ì´ëŸ° ë°©ì‹ìœ¼ë¡œ ì‹œìˆ  êµìœ¡ì„ ì§„í–‰í•´ì•¼ í•©ë‹ˆë‹¤. ì¼ë¶€ í•„ëŸ¬ì˜ ê²½ìš°ì—ëŠ” ì˜ë„ì ìœ¼ë¡œ ëœ ì£¼ì…í•´ì•¼ í•˜ëŠ”ë°, ì´ëŠ” ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì ¤ì´ ë¶€ì–´ì˜¤ë¥´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ê°€ ë°œê²¬í•œ ë°”ë¡œëŠ” ì´ ì ¤ ì œí’ˆë“¤ì´ ë§¤ìš° ê· í˜• ì¡íŒ íŠ¹ì„±ì„ ë³´ì…ë‹ˆë‹¤. ë”°ë¼ì„œ êµìœ¡ì—ì„œëŠ” ìµœì ì˜ êµì •ëŸ‰ì„ ì£¼ì…í•˜ëŠ” ë° ì¤‘ì ì„ ë‘¡ë‹ˆë‹¤. í™˜ìë¥¼ ì‹œìˆ í•  ë•Œ ì›í•˜ëŠ” ìƒíƒœë¡œ êµì •í•˜ë©´ ë˜ë©°, ì ¤ì´ ì†Œì‹¤ë˜ê±°ë‚˜ ë¶€ì¢…ì´ ìƒê¸°ëŠ” ê²ƒì„ ê³ ë ¤í•  í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì²« ë²ˆì§¸ ê¸°ë³¸ ìš”ì†Œì…ë‹ˆë‹¤. ë˜ ë‹¤ë¥¸ ì¤‘ìš”í•œ ìš”ì†ŒëŠ” ì´ ì ¤ì´ ë§¤ìš° ìˆœì‘ë„ê°€ ë†’ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì‹œìˆ  ì‹œ ìƒë‹¹í•œ ìœµí†µì„±ì„ ê°€ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The profile that's been really described to us repeatedly from all the investigators is it has a very low inflammation profile, so you can go much more superficial than you typically could with comparable gels. So again, if anything, it's much more forgiving. And then probably the third basic element is, and we may attribute to just preserving Mother Nature's work, if you will, that HA structure. It's a very efficient gel. So one thing that we seen in the data and that we certainly heard clinically is when you use the gel, it's very efficient in terms of the amount of lift and correction that you have.</td><td>ëª¨ë“  ì„ìƒ ì—°êµ¬ìë“¤ì´ ë°˜ë³µì ìœ¼ë¡œ ì„¤ëª…í•œ íŠ¹ì„±ì„ ë³´ë©´, ì´ ì œí’ˆì€ ë§¤ìš° ë‚®ì€ ì—¼ì¦ í”„ë¡œíŒŒì¼ì„ ê°€ì§€ê³  ìˆì–´ì„œ ê¸°ì¡´ì˜ ìœ ì‚¬í•œ ê²” ì œí’ˆë“¤ê³¼ ë¹„êµí–ˆì„ ë•Œ í›¨ì”¬ ë” í‘œí”¼ ê·¼ì²˜ì— ì‹œìˆ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ì œí’ˆì€ ì˜¤íˆë ¤ ë” ì‹œìˆ ì´ ìš©ì´í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•„ë§ˆë„ ì„¸ ë²ˆì§¸ ê¸°ë³¸ ìš”ì†ŒëŠ”, ì´ëŠ” ìì—°ì˜ ì‘í’ˆì´ë¼ê³  í•  ìˆ˜ ìˆëŠ” íˆì•Œë£¨ë¡ ì‚°(HA) êµ¬ì¡°ë¥¼ ë³´ì¡´í•œ ê²ƒê³¼ ê´€ë ¨ì´ ìˆì„ í…ë°, ì´ëŠ” ë§¤ìš° íš¨ìœ¨ì ì¸ ê²”ì…ë‹ˆë‹¤. ë°ì´í„°ì—ì„œ í™•ì¸í–ˆê³  ì„ìƒì ìœ¼ë¡œë„ ë“¤ì€ ë°”ë¡œëŠ”, ì´ ê²”ì„ ì‚¬ìš©í•  ë•Œ ë¦¬í”„íŒ…ê³¼ êµì • íš¨ê³¼ ì¸¡ë©´ì—ì„œ ë§¤ìš° íš¨ìœ¨ì ì¸ ê²°ê³¼ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤.</td></tr>
<tr><td>So you learn your way through that and you don't have to use as much to get kind of those optimal corrections. I think those are really the three key elements. Operator<br><br>Thank you, thank you for all your questions. At this time, I'd like to turn the call back over to David Moatazedi, President and Chief Executive Officer, for closing remarks. David? David Moatazedi<br><br>Great. Thank you. Evolus is at an inflection point. Clearly we're poised for this next phase of transformative growth. Our relentless execution, market leadership and cash pay, aesthetics and ability to disrupt the status quo have propelled us to this moment.</td><td>ê·¸ë˜ì„œ ìµœì ì˜ êµì •ì„ ì–»ê¸° ìœ„í•´ ë§ì€ ì–‘ì„ ì‚¬ìš©í•  í•„ìš”ê°€ ì—†ì´ ì ì°¨ ìµìˆ™í•´ì§€ê²Œ ë©ë‹ˆë‹¤. ì œê°€ ìƒê°í•˜ê¸°ì— ì´ê²ƒë“¤ì´ ì •ë§ ì„¸ ê°€ì§€ í•µì‹¬ ìš”ì†Œì…ë‹ˆë‹¤. ì§„í–‰ì<br><br>ì§ˆë¬¸í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ë§ˆë¬´ë¦¬ ë°œì–¸ì„ ìœ„í•´ David Moatazedi ëŒ€í‘œì´ì‚¬ê»˜ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. Davidë‹˜? David Moatazedi<br><br>ì¢‹ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. EvolusëŠ” í˜„ì¬ ë³€ê³¡ì ì— ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¶„ëª…íˆ ë‹¤ìŒ ë‹¨ê³„ì˜ í˜ì‹ ì ì¸ ì„±ì¥ì„ ìœ„í•œ ì¤€ë¹„ê°€ ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ëŠì„ì—†ëŠ” ì‹¤í–‰ë ¥, í˜„ê¸ˆ ê²°ì œ ì‹œì¥ì—ì„œì˜ ë¦¬ë”ì‹­, ê·¸ë¦¬ê³  ê¸°ì¡´ ì§ˆì„œë¥¼ í˜ì‹ í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì´ ìš°ë¦¬ë¥¼ ì´ ìˆœê°„ìœ¼ë¡œ ì´ëŒì–´ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With Jevot continuing to outperform the market and our deep customer engagement driving unparalleled loyalty, we are stronger than ever heading into 2025 and beyond. Our expanding global footprint and upcoming launch of Evalisse form and Evolase smooth in early Q2 marks a defining moment for our company, further solidifying our position as the most innovative and fastest growing aesthetics brand. The FDA approval of our first two Evolysse products is the most significant advancement in HA dermal fillers in a decade.</td><td>Jevotê°€ ì§€ì†ì ìœ¼ë¡œ ì‹œì¥ì„ ì•ì„œê°€ê³  ìˆìœ¼ë©°, ê³ ê°ë“¤ê³¼ì˜ ê¹Šì€ ê´€ê³„ êµ¬ì¶•ì„ í†µí•´ íƒ€ì˜ ì¶”ì¢…ì„ ë¶ˆí—ˆí•˜ëŠ” ì¶©ì„±ë„ë¥¼ ì´ëŒì–´ë‚´ë©´ì„œ, ì €í¬ëŠ” 2025ë…„ê³¼ ê·¸ ì´í›„ë¥¼ í–¥í•´ ê·¸ ì–´ëŠ ë•Œë³´ë‹¤ë„ ê°•ë ¥í•œ ì…ì§€ë¥¼ ë‹¤ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ì˜ ê¸€ë¡œë²Œ ì‚¬ì—… ì˜ì—­ì´ í™•ì¥ë˜ê³  ìˆìœ¼ë©°, 2ë¶„ê¸° ì´ˆ ì¶œì‹œ ì˜ˆì •ì¸ Evalisse formê³¼ Evolase smoothëŠ” ë‹¹ì‚¬ì˜ ì „í™˜ì ì´ ë  ê²ƒì´ë©°, ì´ëŠ” ê°€ì¥ í˜ì‹ ì ì´ê³  ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì—ìŠ¤í…Œí‹± ë¸Œëœë“œë¡œì„œì˜ ì…ì§€ë¥¼ ë”ìš± ê³µê³ íˆ í•  ê²ƒì…ë‹ˆë‹¤. ì²« ë‘ Evolysse ì œí’ˆì— ëŒ€í•œ FDA ìŠ¹ì¸ì€ ì§€ë‚œ 10ë…„ê°„ HA(íˆì•Œë£¨ë¡ ì‚°) ë”ë§ í•„ëŸ¬ ë¶„ì•¼ì—ì„œ ê°€ì¥ ì¤‘ìš”í•œ ì§„ì „ì´ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This expansion of our portfolio not only diversifies our revenue streams, but also reinforces our commitment to delivering cutting edge solutions that redefine the aesthetics industry. No company is better positioned to lead this next chapter with a fully integrated digital strategy, an unrelenting focus on millennial consumers, and a business model built for sustainable long term success. I could not be more proud of the culture we built at Evolus and the unwavering commitment of our team to push boundaries and drive results.</td><td>ë‹¹ì‚¬ í¬íŠ¸í´ë¦¬ì˜¤ì˜ í™•ì¥ì€ ìˆ˜ìµì›ì„ ë‹¤ê°í™”í•  ë¿ë§Œ ì•„ë‹ˆë¼, ë¯¸ìš© ì‚°ì—…ì˜ ìƒˆë¡œìš´ ê¸°ì¤€ì„ ì œì‹œí•˜ëŠ” ìµœì²¨ë‹¨ ì†”ë£¨ì…˜ì„ ì œê³µí•˜ê² ë‹¤ëŠ” ìš°ë¦¬ì˜ ì•½ì†ì„ ë”ìš± ê°•í™”í•©ë‹ˆë‹¤. ì™„ë²½í•˜ê²Œ í†µí•©ëœ ë””ì§€í„¸ ì „ëµ, ë°€ë ˆë‹ˆì–¼ ì†Œë¹„ìì— ëŒ€í•œ í™•ê³ í•œ ì§‘ì¤‘, ê·¸ë¦¬ê³  ì¥ê¸°ì ì¸ ì§€ì† ê°€ëŠ¥í•œ ì„±ê³µì„ ìœ„í•´ êµ¬ì¶•ëœ ë¹„ì¦ˆë‹ˆìŠ¤ ëª¨ë¸ì„ í†µí•´ ì´ ìƒˆë¡œìš´ ì¥ì„ ì´ëŒì–´ ë‚˜ê°ˆ ìˆ˜ ìˆëŠ” ê¸°ì—…ì€ ìš°ë¦¬ê°€ ìµœì ì˜ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì €ëŠ” Evolusì—ì„œ ìš°ë¦¬ê°€ êµ¬ì¶•í•œ ê¸°ì—… ë¬¸í™”ì™€, í•œê³„ì— ë„ì „í•˜ê³  ì„±ê³¼ë¥¼ ì°½ì¶œí•˜ë ¤ëŠ” ìš°ë¦¬ íŒ€ì˜ í”ë“¤ë¦¼ ì—†ëŠ” í—Œì‹ ì— ë”í•  ë‚˜ìœ„ ì—†ëŠ” ìë¶€ì‹¬ì„ ëŠë‚ë‹ˆë‹¤.</td></tr>
<tr><td>With our proven ability to execute, we remain focused on delivering industry leading growth and reaching our long term goal of at least $700 million in revenue by 2028. Finally, we look forward to continuing the conversation next week at the Lyrinx and Barclays conferences in Miami. We hope to see many of you there. Thank you for joining us today.</td><td>ìš°ë¦¬ì˜ ì…ì¦ëœ ì‹¤í–‰ ëŠ¥ë ¥ì„ ë°”íƒ•ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì—…ê³„ë¥¼ ì„ ë„í•˜ëŠ” ì„±ì¥ì„ ë‹¬ì„±í•˜ê³  2028ë…„ê¹Œì§€ ìµœì†Œ 7ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì´ë¼ëŠ” ì¥ê¸° ëª©í‘œë¥¼ ë‹¬ì„±í•˜ëŠ” ë° ê³„ì† ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ë‹¤ìŒ ì£¼ ë§ˆì´ì• ë¯¸ì—ì„œ ì—´ë¦¬ëŠ” Lyrinxì™€ Barclays ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ì—¬ëŸ¬ë¶„ê³¼ì˜ ëŒ€í™”ë¥¼ ì´ì–´ê°€ê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ê·¸ê³³ì—ì„œ ë§ì€ ë¶„ë“¤ì„ ëµ™ê¸°ë¥¼ í¬ë§í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Here's a Korean summary of the earnings call in bullet points:<br><br>â€¢ ì‹¤ì  ë° ì‹œì¥ ë™í–¥:<br>- í†¡ì‹  ì‹œì¥ì€ ì§€ì†ì ìœ¼ë¡œ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„¸ë¥¼ ë³´ì´ë©°, íŠ¹íˆ ì Šì€ ì†Œë¹„ìì¸µì˜ ìœ ì…ì´ ê°•ì„¸<br>- íšŒì‚¬ì˜ ì‹œì¥ì ìœ ìœ¨ì´ 14%ì— ê·¼ì ‘í•˜ë©° 2028ë…„ ëª©í‘œì¹˜ë¥¼ ì¡°ê¸° ë‹¬ì„±<br>- í•„ëŸ¬ ì‹œì¥ì€ ì•ˆì •í™” ë‹¨ê³„ì´ë‚˜ ì¤‘ì¥ê¸°ì ìœ¼ë¡œ ì¤‘ìƒìœ„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ ì „ë§<br><br>â€¢ ì‹ ì œí’ˆ Evolysse ì¶œì‹œ:<br>- FDA ìŠ¹ì¸ íšë“ í›„ 2025ë…„ 2ë¶„ê¸° ì´ˆ ì¶œì‹œ ì˜ˆì •<br>- GLP-1 ê´€ë ¨ ì²´ì¤‘ê°ì†Œë¡œ ì¸í•œ ì•ˆë©´ ì£¼ë¦„ ì ì‘ì¦ ë¼ë²¨ íšë“<br>- í˜ì‹ ì ì¸ COLD-X ê¸°ìˆ ë¡œ ê²½ìŸì œí’ˆ ëŒ€ë¹„ ìš°ìˆ˜í•œ ì§€ì†ì„±ê³¼ íš¨ê³¼ ì…ì¦<br><br>â€¢ ì¬ë¬´ ì „ë§:<br>- 2028ë…„ê¹Œì§€ ìµœì†Œ 7ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ ëª©í‘œ ìœ ì§€<br>- êµ­ì œ ì‹œì¥ì—ì„œì˜ ì„±ì¥ì´ ë¯¸êµ­ ì‹œì¥ ì„±ì¥ë¥ ì„ ìƒíšŒí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒ<br>- ê¸°ì¡´ ê³ ê° ê¸°ë°˜ ê°•í™”ì™€ ì‹ ê·œ ì œí’ˆ ì¶œì‹œë¥¼ í†µí•œ ì„±ì¥ ëª¨ë©˜í…€ ê¸°ëŒ€</p>
    <hr style="margin:50px 0;">
    
</body></html>